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Necrotic enteritis (NE) is an economically important enteric disease of broiler chickens 
primarily caused by α-toxin (Cpα) secreted by C. perfringens type A. Mice immunized with 
recombinant C-terminal domain of Cpα (CpαCD) had transient and fewer localized lesions 
upon challenge with C. perfringens type A. These results demonstrate the usefulness of 
CpαCD as an immunogen for vaccine development against NE for chickens. Chicken CD40 
(chCD40) is mainly expressed on the surface of chicken antigen-presenting cells (APCs), and 
the interaction of chCD40 and chCD40L (natural ligand for chCD40) provides crucial 
activation signals for chicken B-cells. A hypothesis was proposed that in ovo vaccination with 
an adenovirus-vectored CpαCD vaccine capable of targeting immunogen to APCs through the 
CD40 pathway will improve protection against NE in chickens. One agonistic monoclonal 
anti-chCD40 antibody (designated 2C5) was produced and characterized. 2C5 not only 
detected expression of chCD40 on chicken APCs, but also induced NO synthesis in chicken 
HD11 macrophages and enhanced proliferation of serum-starved chicken DT40 B-cells. This 
demonstrated substantial functional equivalence of 2C5 with chCD40L. The potential of 2C5 
as an immunological adjuvant was further assessed by targeting a hapten to chicken APCs in 
hopes of enhancing an effective IgG response. Seven-week old chickens were immunized 
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subcutaneously once with a complex consisting of 2C5 and peptide, and relative 
quantification of the peptide-specific IgG response showed that this complex was able to 
elicit a strong IgG response as early as four days post-immunization. This demonstrates that 
CD40-targeting antigen to chicken APCs can significantly enhance antibody responses and 
induce immunoglobulin isotype-switching. An agonistic anti-chCD40 single-chain variable 
fragment (designated DAG1) was combined with an adenoviral delivery system to create a 
vaccine, Ad-(DAG1-CpαCD-FLAG), for in ovo administration. The efficacy of in ovo 
vaccination of broilers with Ad-(DAG1-CpαCD-FLAG) in controlling NE was evaluated by C. 
perfringens type A challenge at 18 days post-hatch. Neither statistically significant IgA / IgG 
response nor protection against C. perfringens type A challenge was found in the vaccinated 
birds. These preliminary data suggest that a super-optimal dose of Ad-(DAG1-CpαCD-FLAG) 
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Necrotic enteritis (NE) is an economically important enteric disease of modern 
chickens primarily caused by infection with Clostridium perfringens type A (Cooper and 
Songer, 2009). The acute form of NE in a broiler flock can account for 1% losses per day, for 
several consecutive days during the last weeks of the rearing period (Cooper and Songer, 
2009). Combined with the broiler meat production estimate recently, the cost of NE 
including clinical and subclinical infections was close to $2 billion US dollar worldwide (Lee 
et al., 2011). In addition, some strains of C. perfringens also produce enterotoxins that cause 
food-borne disease in humans (Collie and McClane, 1998). 
NE is suspected to occur under certain predisposing conditions when C. perfringens 
type A, and to a lesser extent type C multiply in excess numbers and secrete toxins in small 
intestine that was previously damaged by Eimeria (Songer, 1996). Due to the voluntary or 
legally required withdrawal of the use of antibiotic growth promoters in feed, few tools and 
strategies are available for efficient prevention and control of NE in chickens. The economic 
toll of this disease is only expected to rise, as therapeutic agents become increasingly 
unavailable, and management practices are altered (Cooper and Songer, 2009). Vaccine is 
considered as the most promising method for prevention of NE, but no efficient vaccine 
against NE for chickens is available on the market to date (Lee et al., 2011).  
C. perfringens type A produces several exotoxins, and the predominant one is α-toxin, 
which belongs to phospholipase superfamily (Titball et al., 1991). C. perfringensα-toxin 
______________________ 
This dissertation follows the style and format of Journal of Immunological Methods. 
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(Cpα) is one of the most potent toxic phospholipases characterized to date (Titball et al., 
1993). C. perfringens α-toxin (Cpα) is one of the most potent toxic phospholipases 
characterized to date (Titball et al., 1993). Cpα has been implicated as the major cause of 
lesions associated with NE (Al-Sheikhly and Truscott, 1977a), and is also known as 
contributor in the pathogenesis of a variety of diseases, such as gas gangrene in humans, in 
different animal species (Cooper and Songer, 2009). Several studies have shown that 
immunization with crude Cpα as immunogen can induce protection against diseases caused 
by C. perfringens. Mice immunized intraperitoneally with a recombinant C-terminal domain 
of Cpα (amino acid 247-370) had transient and localized lesions compared to sham 
immunized mice upon challenge with C. perfringens type A. At a high dose challenge (3.74 x 
109 cfu), there were no survivors in the control group, whereas 90% of mice in the 
immunized group survived. This demonstrates the usefulness of the C-terminal domain of the 
Cpα as an immunogen for development of vaccine against NE for chickens (Stevens et al., 
2004). 
The interaction between CD40 [mainly expressed by antigen presenting cells (APCs)] 
and CD154 (expressed by T-cells) mediates the major signal in T-cell help to B-cells 
(Banchereau et al., 1994). It drives or co-stimulates activation, proliferation, differentiation, 
and antibody production on B-cell (Xu and Song, 2004). Using CD40-targeted antigen 
delivery, up to 1000-fold increased antibody responses were reported in mice (Barr et al., 
2003). Agonistic anti-CD40 antibodies not only target antigen delivery and activate B-cells, 
but also induce antibody class-switching (Barr et al., 2006). Murine and human naïve B-cells 
can be activated with agonistic anti-CD40 antibody or CD40L to undergo class switch 
recombination on immunoglobulin gene in vitro (Kracker and Radbruch, 2004). 
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Immunoglobulin class switching through CD40 pathway is most crucial for mucosal 
immunity because IgA is readily transported across the intestinal mucosa and is endowed 
with effector properties that are critical for the local humoral immune response (Zan et al., 
1998). Recently, CD40-mediated enhancement of isotype-switched antibody responses 
against a hapten in chickens was evaluated (Chen et al., 2012). Adjuvant effects of agonistic 
anti-chicken CD40 antibody were observed while a hapten was biologically complexed to it. 
Significant hapten-specific and isotype-switched antibody responses were observed only four 
days after a single immunization with very low amount of antigen, and significant hapten-
specific antibody response had been maintained for two weeks. 
Using recombinant replication-defective human adenoviruses, such as adenovirus type 
5 (Ad5) has many advantages for vaccine development because vectored adenovirus vaccine 
can be generated rapidly and mass-produced at low cost (Avakian et al., 2007). First, they are 
able to introduce foreign gene into a wide spectrum of host cells. Second, transduced gene is 
transiently maintained and expressed for several weeks in host cells, which produces 
reasonable immunity against the foreign protein. Finally, despite its human origin, Ad5 is 
able to target foreign genes in a wide range of animal species, even those in which Ad5 
cannot replicate (Ali et al., 1994). Transduction of chicken embryotic cells in vivo by 
replication-defective Ad5 was reported for the first time in 1995 (Adam et al., 1995). In ovo 
delivery of vectored adenovirus vaccines makes it possible to administer a wide variety of 
pathogen derived antigens in large scale and deliver high potency in a single-dose regimen, 
which does not interfere with epidemiological surveys of natural infections. At the 
experimental level, antigen delivery by Ad5 can also avoid the interference by maternal 
immunity while in ovo administration route is required (Breedlove et al., 2011). 
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In ovo vaccination plays an important role in protecting chickens from several diseases 
(Josefsberg and Buckland, 2012). In ovo injection system vaccinates up to 70,000 
embryonated chicken eggs per hour in a more uniform and precise manner than post-hatch 
mass vaccination methods (Perez and Ronchi, 1996). Today, approximately 90% of broiler 
chickens grown in the USA are vaccinated in ovo 2-3 days prior to hatch at the time when 
eggs are transferred from the incubator to the hatcher (Avakian et al., 2007). Antigen 
delivery by adenovirus to the amniotic fluid of the embryo is highly effective because during 
E17-19, the embryo imbibes the amniotic fluid, and vectored adenovirus can rapidly 
transduce cells on the respiratory tract (Sharma et al., 2002) and the digestive system 
(Kapczynski et al., 2003). These results in highly efficient antigen delivery to the mucosa-
associated lymphoid tissue (MALT) as well as Peyer's patches, the most important secondary 
lymphoid organ for mammals, proposed for chickens, in mucosal immunity. Exposure to 
antigen drives the maturation of avian MALT (Reese et al., 2006) and suggests that in ovo 
immunization may accelerate the maturation of embryonic Bronchus-Associated Lymphoid 
Tissue (BALT) (Moyron-Quiroz et al., 2004). In addition, the hexon protein on adenovirus is 
highly immunogenic and confers adjuvant activity to exogenous antigens (Molinier-Frenkel 
et al., 2002). 
The goal of this study is to produce and evaluate an in ovo delivered vectored 
adenovirus vaccine for the prevention and control of C. perfringens-associated morbidity and 
mortality in poultry. By fusing in-frame, the single-chain variable fragment (scFv) to another 
molecule, a moiety can be achieved that is specific for a particular target with an enhanced 
function (Todorovska et al., 2001). One agonistic anti-CD40 scFv (DAG1) was fused to 
CpαCD for a targeted, more efficient delivery to APCs in order to enhance CpαCD specific 
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antibody response. This DAG1-CpαCD chimera was further cloned into an adenoviral vector 
for adenovirus production for in ovo vaccination. This in ovo vaccination with a non-
replicating human adenovirus vector expressing DAG1-CpαCD is a novel concept for 
induction of C. perfringens α-toxin specific IgA responses because it will direct active uptake 
of the CpαCD by APCs, and simultaneously provide well-characterized signals for both APC 
activation and IgA switch factor through CD40 signaling. This CD40-targeting strategy will 
improve clinical efficacy of a C. perfringens α-toxin vaccine and this outcome will be 
significant because an efficacious vaccination strategy against NE will contribute to an 
increase in the efficiency of poultry production systems. More broadly, this vaccine delivery 
system will provide an opportunity for a systematic evaluation of further modifications that 



















REVIEW OF LITERATURE 
 
Necrotic enteritis (NE) 
The poultry industry has grown conspicuously and transformed itself into a highly 
specialized field over the past 40 years; substantial economic investment, like vaccination, is 
required (Chapman et al., 2003; Cooper and Songer, 2009). Higher efficiency of growth, feed 
conversion, and meat yield of poultry is highly improved by genetic selection (Cooper and 
Songer, 2009). These advances result in higher producing rates of poultry and save 65-70% 
of total cost investing in feed (Cooper and Songer, 2009). However, the profit of poultry 
industry is greatly affected by unexpected high mortality in flocks caused by infectious 
diseases. One of these is necrotic enteritis (NE), an economically important enteric disease 
with high mortality rate in poultry primarily caused by Clostridium perfringens type A 
(Craven et al., 1999), which is estimated to cost the international poultry industry more than 
$2 billion US dollar per year (McReynolds et al., 2004). The occurrence of NE in poultry has 
been well documented since it was first diagnosed in 1961. During the 1970s, Al-Sheikhly 
and colleagues suggested that α-toxin produced by C. perfringens was the main virulence 
factor involved in pathogenesis of NE (Al-Sheikhly and Truscott, 1977a; Al-Sheikhly and 
Truscott, 1977c; Al-Sheikhly and Truscott, 1977b). This suggestion was based on the 
observations that α-toxin is a major secreted toxin from C. perfringens, and filtered culture 
media from C. perfringens can still cause necrotic lesions typical of NE in the 
gastrointestinal tract of chickens (Al-Sheikhly and Truscott, 1977c; Al-Sheikhly and Truscott, 
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1977b). Subsequent reports also demonstrate that α-toxin was the prerequisite virulence 
factor for development of NE (Al-Sheikhly and Truscott, 1977a; Fukata et al., 1988). 
Because of the suddenly increased mortality found in affected chickens, clinical or 
subclinical NE has devastating effects on poultry industry (Gholamiandehkordi et al., 2007). 
Clinical signs in chickens suffering from clinical NE include depression, decreased feed 
intake, reluctance to move, ruffled feathers, and diarrhea (Hermans and Morgan, 2007), and 
affected ones can die acutely. Daily mortality rates can attain 1% per flock. Without medical 
treatment, 10-40% of chickens in an affected flock may die. Subclinical NE (milder form) is 
more common in the poultry industry, and may exert a significantly negative impact on 
production. Subclinical NE often goes undetected, and hence affects the animal welfare when 
medical treatment is not provided. Due to damage of the intestinal mucosa, and subsequent 
decreased digestion and absorption, sick chickens exhibit decreased weight gain, and 
increased feed conversion ratio. The productivity of each flock can be greatly affected 
(Kaldhusdal et al., 1999). The mildest form of NE induces no visible illness on chickens but 
is associated with temporarily reduced weight gain, impaired feed conversion ratio, and 
increased condemnation rates at slaughter due to liver lesions. 
 
C. perfringens 
C. perfringens is a gram-positive, spore-forming, anaerobic enteropathogen that is 
naturally found in soil, water, sewage, and intestinal environments of humans and animals 
(Hatheway, 1990). Genomic analysis revealed that C. perfringens lacks the genetic 
machinery to produce 13 essential amino acids, and can only obtain them in vivo by lysing 
host cells via actions of exotoxins, which are phospholipase or pore-forming enzymes (Myers 
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et al., 2006). Reports indicate that more than 17 toxins or potentially toxic exoproteins are 
produced by C. perfringens, which are classified into toxigenic serotypes A, B, C, D, and E 
based on their ability to produce five major toxins: α, β, ι, ε, and θ (Brynestad and Granum, 
2002). C. perfringens is the causative agent of a number of diseases, including NE, gas 
gangrene, and type A diarrhea in both humans and chickens (Brynestad and Granum, 2002). 
In fact, C. perfringens is one of the most frequently isolated bacterial pathogens in food 
borne disease outbreaks, after pathogens such as Campylobacter and Salmonella (Buzby and 
Roberts, 1997). Frequent fatal outbreaks have been attributed to C. perfringens food 
poisoning (Briggs et al., 2011). The spore-forming feature of C. perfringens and its ability to 
multiply and survive in food at a range of temperatures, have led to detection of this 
organism in a multitude of raw and processed foods, namely meat, meat products, and spices 
(Brynestad and Granum, 2002). 
C. perfringens can also survive under variable environmental conditions in extended 
periods in poultry farms (Van Immerseel et al., 2004). Colonization of the avian intestinal 
tract by C. perfringens appears to be a very early event in the life of the animals, and can be 
transmitted within an integrated operation (Craven et al., 2003). Although several subtypes of 
C. perfringens may be presented in healthy chickens and even in those with subclinical 
symptoms, subtypes isolated from sick chickens in different flocks may differ. C. perfringens 
type A is reported to be the main pathogen proliferating in chickens with clinical NE (Yoo et 
al., 1997) and has also been isolated from livers with cholangiohepatitis in sick chickens 
(Kaldhusdal et al., 2001; Lovland and Kaldhusdal, 2001; Lovland et al., 2004). C. 
perfringens type C is also reported to be associated with NE, but most cases appear to be 
caused by type A (Thompson et al., 2006). 
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The two most well-known forms of C. perfringens associated disease in chickens are 
NE and cholangiohepatitis (Lovland and Kaldhusdal, 1999). Cholangiohepatitis is usually 
detected on the carcass at slaughter houses or as an incidental finding during exploratory 
surgery on chickens or necropsy of chickens collected during the rearing period. Clinical and 
subclinical NE are often found in chickens affected by cholangiohepatitis (Cooper and 
Songer, 2009). NE is most commonly found in broilers, young replacement broiler breeders, 
and young meat turkeys. Broilers at two to five weeks of age are most frequently affected, 
and C. perfringens is also found frequently in intestinal contents of broiler from 2 weeks of 
age and throughout the rearing period though (Long and Truscott, 1976). NE is also regularly 
found in layers, mostly in pullets and young layers kept on litter (Lovland and Kaldhusdal, 
1999). Low level maternal immunity against C. perfringens is associated with an increased 
risk of NE in broilers. Broiler chicks are particularly susceptible to NE when maternal 
antibodies have waned and the level of actively produced specific antibodies is still low, 
especially those broiler chicks from young parent hens have lower levels of maternal 
antibodies against C. perfringens (Lovland et al., 2004). 
 
C. perfringens α-toxin (Cpα) 
α-toxin is encoded by the phospholipase gene reported to be highly conserved in C. 
perfringens strains isolated from sick chickens, with variations in only nine out of 397 
deduced amino acid positions. α-toxin is a zinc metallophospholipase possessing activities of 
both phospholipase C and sphingomyelinase (Saint-Joanis et al., 1989). It contains an α-
helical N-terminal domain (CpαND, residues 1–246) encompassing the active site (Titball et 
al., 1993) and a β-sandwich C-terminal domain (CpαCD, residues 256–370) considered 
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essential for membrane binding (Titball et al., 1991; Titball et al., 1993; Nagahama et al., 
1998; Naylor et al., 1998). α-toxin destroys cell membranes by oxidation and hydrolysis of 
membrane phospholipids, and also enters the blood stream, causing systemic effects and 
death (Thompson et al., 2006). CpαND exhibits a strong sequence homology to the entire 
Bacillus cereus phospholipase C (PLC), which is non-toxic. The recombinant CpαND retains 
its PLC activity but loses its hemolytic or lethal activity with a markedly reduced 
sphingomyelinase activity. However, these activities are restored in the presence of 
recombinant CpαCD. This complementation occurs probably due to hydrophobic interactions 
of the two domains (Titball et al., 1993). The CpαCD by itself has no enzymatic/toxic 
activities but is involved in cell-membrane disruption (Titball et al., 1993). Neither CpαND 
nor CpαCD is cytotoxic by itself, whereas α-toxin is cytotoxic to mouse lymphocytes. 
Antiserum raised against CpαCD has equal potency to antiserum against α-toxin in 
neutralizing the PLC and hemolytic activities of the holoenzyme in vitro, leading to the 
conclusion that the CpαCD is a good immunogen for vaccine development (Stevens et al., 
2004). 
While α-toxin was previously believed to be the main virulence factor involved in NE 
pathogenesis in chickens (Al-Sheikhly and Truscott, 1977c; Fukata et al., 1988; Williamson 
and Titball, 1993; Thompson et al., 2006), the recent identification of necrotic enteritis toxin 
B (NetB) and hypothetical protein (HP) produced by C. perfringens, which is related to NE, 
has called the validity of this concept into question (Keyburn et al., 2006; Keyburn et al., 
2008; Kulkarni et al., 2008; Olkowski et al., 2008). Although NetB / HP was demonstrated to 
be critical for the ability of C. perfringens to cause NE and its identification provides a 
significant opportunity for the development of novel vaccines against NE in poultry, most of 
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the solid evidence of the role of NetB / HP pathogenesis in NE is currently still under 
investigation (Sumners et al., 2012). 
 
Pathogenesis of NE 
Although the pathogenesis of NE is not completely understood, the presence of C. 
perfringens in the intestine alone is insufficient to induce NE, and two requirements for 
induction of NE in chickens have been proposed (Al-Sheikhly and Truscott, 1977a). First, 
preexisting damage to the intestinal mucosa caused by predisposing factors, such as 
coccidiosis. Second, higher numbers of C. perfringens than would typically exists in normal 
flora of the chicken intestine. If these two requirements are fulfilled sequentially, 
development of lesions often starts at the tips of the villi. The damaged villi are observed 
where C. perfringens adhere, proliferate, denude lamina propria, and induce coagulative 
necrosis. Attraction and lysis of heterophils can cause further tissue necrosis, as makes 
bacterial proliferation proceed rapidly. 
Mucosal damage induced by Eimeria parasites is reported to be the most important 
predisposing factor because this damage on epithelial surface of the intestinal tract allows for 
the establishment of C. perfringens (Johansson and Sarles, 1948; Nairn and Bamford, 1967; 
Helmboldt and Bryant, 1971). Although coccidia do not induce lesions in the small intestine 
where lesions of NE usually develop, caecal coccidiosis may increase the shedding of C. 
perfringens resulting in the contamination of the rearing environment (Baba et al., 1992). 
The pathogenic mechanism of cholangiohepatitis, the most common C. perfringens 
associated liver disease, has been reproduced experimentally by inoculation with C. 
perfringens / C. perfringens toxins into the hepatoenteric bile duct (Nairn and Bamford, 1967; 
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Kaldhusdal et al., 2001). These results suggest that C. perfringens / C. perfringens toxins 
may reach the liver and lead to bile stasis and inflammation of the biliary tract. The incidence 
of cholangiohepatitis shows a striking parallel with the incidence of NE, which suggests that 
this is another manifestation of clinical / subclinical NE, and that C. perfringens is the 
etiology of the disease / lesions  (Lovland and Kaldhusdal, 2001; Van Immerseel et al., 2004). 
Horizontal transmission has been considered as the significant means of dissemination 
of C. perfringens, but recent findings suggest that even vertical transmission is possible 
(Shane et al., 1984). C. perfringens may be transmitted between facilities within an 
integrated broiler chicken operation. Molecular subtyping of C. perfringens isolates suggests 
that organisms contaminating the processed product could originate from the poultry 
environment prior to grow out (Dhillon et al., 2004). 
 
Controlling NE 
The predisposing factors leading to outbreaks of NE in chickens are exceedingly 
important (Van Immerseel et al., 2004). Overcrowding of chickens kept on litter, inadequate 
hygiene routines, wet litter problems, and feed composition are the main issues (Nairn and 
Bamford, 1967; Helmboldt and Bryant, 1971). The risk of NE is low when chickens are kept 
on wire floor that minimizes contact with feces, but NE outbreaks occasionally appear even 
in chicken kept on wire floors (Craven et al., 2001; Craven et al., 2003; Van Immerseel et al., 
2004). Another predisposing factor of NE outbreak is the feed, which may be contaminated 
with C. perfringens despite the pelleting process or heat treatment (Nairn and Bamford, 1967; 
Eleazer and Harrell, 1976; Hofacre et al., 1986). Sudden changes in rations of feed 
component can alter the intestinal pH and native microbial population, and give rise to 
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opportunistic bacteria such as C. perfringens (Apajalahti et al., 2001). Several studies 
indicate that maize/wheat based feed may contribute to the prevention of NE because these 
feeding ingredients have been reported to lower the pH of gizzard contents and reduce 
intestinal counts of C. perfringens (Prescott, 1979; Cooper et al., 2009). Some diets 
containing indigestible, water soluble, non-starch polysaccharides known to increase the 
viscosity of the ingesta, such as barley, wheat, maze, and rye, have also been incriminated as 
predisposing factors for NE (Branton et al., 1997). The source of dietary fat can also be 
important. Intestinal counts of C. perfringens in broilers fed with food supplied with soy-oil 
were lower than those with lard/tallow (Williams, 2005). High levels of crude dietary 
proteins may also be a risk factor (Truscott and Al-Sheikhly, 1977; Dahiya et al., 2005) 
because these differences between protein ingredients have been correlated with dietary 
glycine levels. Dietary glycine level and C. perfringens counts experiments suggest high 
levels of glycine are a predisposing factor for NE (Dahiya et al., 2005). Dietary animal 
protein was reported to be associated with a higher risk of NE than other relevant protein 
sources from plants (Long, 1973; Van Immerseel et al., 2004; Gholamiandekhordi et al., 
2006; Olkowski et al., 2006), and especially fish meal is considered a frequent source of 
contamination of C. perfringens (Drew et al., 2004). 
Controlling NE was commonly achieved in a preventive manner, thus antimicrobial 
drugs are added in feed or water. However, the use of antibiotics in this manner was banned 
by the European Union because of the concern about that routine prophylactic use of 
antibiotics may contribute to problems of antimicrobial resistance (Emborg et al., 2003; 
Glassmeyer et al., 2005). This policy makes NE become much more widespread (from 4% to 
12.4%), especially in Western Europe, and investigation of alternative control measures are 
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highly needed (Jiang et al., 2009). Increasing restrictions on the use of in-feed antimicrobials 
in Europe and other regions promotes the interest in non-antimicrobial measures against NE. 
Developing a non-antimicrobial preventive strategy against this disease is one of today’s 
major challenges with regard to poultry health and welfare. 
Non-antimicrobial feed additives and oral treatments have been proposed as potential 
preventive measures for NE, these include probiotics or competitive exclusion products, 
plant-derived products, non-digestible compounds assumed to promote a healthy gut flora, 
supplementary enzymes and acids (Casewell et al., 2003; Collier et al., 2003; Drew et al., 
2004; Van Immerseel et al., 2004). Promising effects in terms of suppressing growth of C. 
perfringens, and in some cases prevention of NE, have been reported for products within all 
of these groups of oral treatments but so far no single alternative measure as effective as the 
in-feed antimicrobials has been found. Based on naturally occurring antibodies or maternal 
vaccination against C. perfringens, some studies suggest that specific humoral immune 
response against α-toxin provides a good degree of protection against NE (Zekarias et al., 
2008; Cooper et al., 2009; Jiang et al., 2009). Vaccines against NE in poultry are not yet 
available but experimental work suggests that vaccination may become a significant 
contribution to the preventive efforts. Several studies indicate that the crude α-toxin as an 
immunogen induces good protection (Hoang et al., 2008; Zekarias et al., 2008). 
 
CD40 
CD40, an integral membrane glycoprotein of the TNF-receptor super family, is 
expressed mainly on professional antigen-presenting cells (APCs), including B-cells, 
macrophages, and dendritic cells (van Kooten and Banchereau, 2000). However, in mammals, 
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expression of CD40 is not restricted to APCs. Reports indicate that high levels of CD40 can 
also be detected on a wide range of human cancer cells from the bladder, breast, and ovary 
(Sabel et al., 2000; Hill et al., 2005). 
The natural ligand for CD40 is CD154 (CD40L) and it is transiently expressed on 
activated CD4+ T-cells (Armitage et al., 1992). In addition, platelets are also reported to be a 
major source of secreted CD40L. The engagement of the T-cell bound CD154 ligand to the 
CD40 receptor on APCs provides the critical signal required for optimal APC activation 
which results in up-regulation of MHC and CD40 molecules, expression of CD80/86, and 
secretion of cytokines (Grewal and Flavell, 1996; Noelle, 1996). These outcomes are critical 
for optimal priming and expansion of antigen-specific effector and memory T-cells, B-cell 
response, and immunoglobulin class switching (Gordon and Pound, 2000). The importance 
of CD40–CD40L ligation has been clearly demonstrated by the human hyper-IgM syndrome 
and immune deficiencies found in CD4 knockout mice; B-cells from such CD4- mice cannot 
undergo immunoglobulin class switching in response to T-cell dependent antigens (Monson 
et al., 2001). In vitro stimulation of APCs using various forms of CD40 agonists like 
membrane-associated CD40L, soluble CD40L, or anti-CD40 antibodies evokes distinct 
functional responses (Fanslow et al., 1994). Soluble CD40L is considered to be a pro-
inflammatory cytokine because it has been shown to be involved in chronic inflammatory 
diseases like autoimmune disorders, arthritis, atherosclerosis, and even cancer (Laman et al., 
1997; Cooke et al., 1999) . Elevated levels of soluble CD40L are also significantly associated 
with high risk for diabetes (Santilli et al., 2007), coronary and cerebrovascular 
atherosclerosis (Lobbes et al., 2006), and hypertensive and autoimmunity diseases (Desideri 
et al., 2007). 
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Agonistic anti-CD40 antibodies/recombinant CD40L have been successfully used as 
substitutes for T-cell help to regulate the activities of APCs both in vitro and in vivo in 
mammals and chickens (Bennett et al., 1998; Kothlow et al., 2008; Chen et al., 2010). 
Agonistic monoclonal antibodies (mAbs) against mouse CD40 have also been shown to 
directly mimic T-cell help in vivo in response to T-cell dependent / independent antigens in 
mice (Barr and Heath, 1999; French et al., 1999). Direct mimicking of T-cell help to B-cells 
by agonistic anti-CD40 mAbs may have therapeutic value in a T-cell deficiency syndrome 
like AIDS and hyper-IgM syndrome (Barr et al., 2003). Agonistic anti-CD40 mAbs can also 
confer a potent adjuvant effect when chemically conjugated with antigen, and the adjuvant 
effect can be attained against any physically attached antigen inducing protective immune 
responses against pathogens or tumors (Barr et al., 2003; Barr et al., 2006). 
 
Agonistic monoclonal anti-CD40 antibody-based targeted vaccine 
While there is great potential for novel vaccines based on recombinant proteins and 
synthetic peptides, such antigens often lack the immunogenicity of whole killed pathogens 
used in traditional vaccines. Novel vaccines require potent immunological adjuvants to 
render the antigens sufficiently immunogenic. Thus, the identification of immunological 
adjuvants with low reactogenicity and high potency to enhance humoral immune responses is 
quite necessary (Barr et al., 2003). Most immunologic adjuvants work through pattern 
recognition receptors, such as Toll-like receptors, on leukocytes by mimicking a danger 
signal to the immune system. These adjuvants induce release of cytokines, which often 
results in side effects at the injection site or systemic allergy (Rock et al., 2005). Arguably 
one of the most successful strategies to attain this end consists of attaching the antigen to an 
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antibody against a co-stimulatory cell surface receptor expressed by antigen presenting cells 
(APC), such as CD40 (Barr et al., 2006). A novel strategy of vaccine development using 
agonistic anti-CD40 antibody mAb, was reported to work directly on APCs with low 
reactogenicity but high immunogenicity. This strategy was able to enhance humoral immune 
responses 1000-fold compared with the use of an aluminum based adjuvant (Barr et al., 
2006), and may avoid the inflammatory side effects induced by most adjuvants (Gendelman 
et al., 2005; Barr et al., 2006; Hamzah et al., 2008). 
Unlike the activation pathway through pattern recognition receptors, Barr and co-
workers reported that the adjuvant effect of agonistic anti-CD40 mAb is attributed to the 
CD40 binding domain and mediated by simple direct targeting and stimulating of B-cells, not 
through Fc receptor (Barr et al., 2003). Agonistic anti-CD40 mAb can directly mimic T-cell 
help to enhance humoral immune responses to T-cell dependent antigens; similar effects are 
also found when the same antigen is given with T-cell independent antigens and cytokines, 
such as IL-4, in vivo (Barr et al., 2003). Agonistic anti-CD40 antibodies not only target 
antigen delivery and activate B-cells, but also induce antibody class-switching. Murine and 
human naïve B-cells can be activated with anti-CD40 mAbs or CD40L (CD154) to undergo 
class switch recombination in vitro (Petersen et al., 2006). This is crucial, because IgA is 
readily transported across the intestinal mucosa and is endowed with effector properties that 
are critical for the local humoral immune response (Ravdin et al., 2006). 
For T-cell independent antigens, administration of the anti-CD40 mAb with type III 
pneumococcal capsular polysaccharide induced the generation of strong, isotype-switched 
humoral immune responses, which are protective and extremely persistent (Diehl et al., 1999; 
French et al., 1999; Sotomayor et al., 1999; Ninomiya et al., 2002; Hatzifoti and Heath, 
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2007). This provides a good solution to overcome a major deficiency with polysaccharide 
based vaccines for infants and young children who fail to respond to many T-cell 
independent antigens. Activation through CD40 on B-cells by the administration of agonistic 
anti-CD40 mAb or recombinant CD40L in combination with cytokines leads to 
immunoglobulin class switching in a similar way as the stimulation of LPS plus cytokines 
(Diehl et al., 1999; French et al., 1999; Sotomayor et al., 1999; Ninomiya et al., 2002; Barr et 
al., 2003; Barr et al., 2005; Barr et al., 2006). The adjuvant effect of agonistic anti-CD40 
mAb is T-cell independent, which is a definite advantage for the vaccination of patients with 
CD4 deficiencies, like those infected with HIV. 
The induction of cell-mediated immunity has also been shown by synergistic activity 
with administration of agonistic anti-CD40 mAbs in mammals (Jabara et al., 1990; Schwabe 
et al., 1997; Khalil and Vonderheide, 2007). Antigen-specific CD8+ T-cells can be elicited 
from combination of stimulation with a Toll-like receptor (TLR) agonist and agonistic anti-
CD40 mAb, and this combination optimizes the efficiency of a vaccine in eliciting both cell-
mediated and humoral immunity (Ahonen et al., 2004; Barr et al., 2005).  
Besides enhancing specific humoral immune responses, another concern of a vaccine is 
the long-term protection against specific immunogens. A potent enhancement of anamnestic 
responses against a second injection of antigen alone was reported (Barr et al., 2003), 
indicating a strong boosting of immunological memory. This formation of immunological 





Single-chain variable fragment (scFv) 
However, large-scale of growing hybridoma for producing mAb is expensive and 
highly concentrated mAbs can only be produced in mouse ascites. Unfortunately, production 
of mAbs in mouse ascites has negative animal welfare implications, and several countries 
have legislation limiting antibody production in mouse ascites. These factors restrict the use 
of mAb based tests, vaccines, and therapeutics.  
The scFv technology, cloning of a fusion protein of the variable domains of the heavy 
(VH) and light chains (VL) of immunoglobulin, is an alternative for classical monoclonal 
antibody preparation, which allows rapid but cheap production of functional proteins in 
substantial quantities. The smallest functional fragment of an antibody, which is composed of 
merely VH and VL, retains the binding site and specificity of the whole immunoglobulin 
molecule. The recombinant version of these fragments of variable regions, which lacks the 
constant region, are made into a more stable binding single chain fragment by covalently 
linking the two domains with a flexible polypeptide linker. The specificity is usually 
unaltered (Peterson and Adham, 2006). These molecules were created to facilitate phage 
display, where it is highly convenient to express the antigen-binding domain as a single 
peptide (Marks et al., 1991). As an alternative, scFv can also be created directly from 
subcloned VH and VL derived from a hybridoma instead of hyper-immune mouse splenocytes 
(Chaudhary et al., 1990). 
VH and VL are usually joined together with a short linker peptide of 7 to 15 amino 
acids to form a monomer. The linker is rich in glycine for flexibility, as well as serine / 
threonine for solubility, and can either connect the N-terminus of VH with the C-terminus of 
the VL, or vice versa (Holliger et al., 1993). Shorter linkers (one / two amino acids) can also 
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lead to the formation of scFv trimmers (tribodies) and tetramer (tetrabodies) (Ravn et al., 
2007). While the linker peptide was too short (five to seven amino acids), VH and VL cannot 
fold together by noncovalent binding. This scFv are forced to dimerize to form dimer known 
as diabody (Holliger et al., 1993). Diabodies are reported to have dissociation constant up to 
40-fold lower than other corresponding scFv monomer (Holliger et al., 1993). The lower 
dissociation constant means diabody has much higher affinity to its corresponding antigen 
and may be a functional substitute of complete immunoglobulin (Le Gall et al., 1999). All of 
these different forms of scFv can be further modified to compose from different sets of VH 
and VL with specificity for more than a single antigen, in which case they are functional 
equivalence to bispecific antibodies (Muller and Kontermann, 2010). 
A bispecific mAb (BsMAb) is a recombinant protein that is composed of two sets of 
VH and VL from two different mAbs separately, and consequently can bind to two different 
types of antigen (Sarkar et al., 2012). The most widely used application of this BsMAb is in 
cancer immunotherapy, where BsMAbs are engineered to bind to cytotoxic T-cell (CD3+) 
and tumor cells simultaneously. In sum, tumor cells will be linked to few cytotoxic T-cells in 
the microenvironment, which will be destroyed by released cytotoxins perforin, granzymes, 
and granulysin (Lindhofer et al., 1995; Baeuerle and Reinhardt, 2009). The latest 
development of BsMabs is the bispecific tandem di-scFvs, known as bi-specific T-cell 
engagers (BiTEs) (Baeuerle and Reinhardt, 2009; Muller and Kontermann, 2010). 
ScFvs diabodies have many applications like antigen-binding domains of artificial T 
cell receptors (Kolly et al., 2007), and sometimes can be functional substitute of classical 
antibodies in flow cytometry and immunohistochemistry (Gray et al., 2010). Unlike 
monoclonal antibodies, which are often produced in mammalian cell cultures, scFvs can be 
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in either prokaryotic or eukaryotic expression system (Peterson et al., 2006a). The scFv can 
then be modified for expression in a variety of systems, and for various applications, such as 
vaccine development and immunotherapy (Holliger et al., 1993). By fusing in-frame, the 
scFv to another molecule, a moiety can be achieved that is specific for a particular target with 
an enhanced function (Todorovska et al., 2001). Consequently, for highly specific targeting 
cells in vivo, the dose of therapeutic scFv diabody drug can be much lower than classical 
antibodies (Adams et al., 1998). 
 
Adenovirus-mediated antigen delivery in ovo 
Multiple experimental recombinant vaccines have been developed for chickens in 
many years, some of which have been reported to efficiently protect chickens from diseases, 
especially from avian influenza (Toro et al., 2007). The distinct advantage of vectored 
vaccines, especially live replication-defective vectored adenovirus, is the ability to introduce 
highly specific and well-defined antigens that can be the focus of specific immune reactivity 
without the risk of generating virulent revertants (Breedlove et al., 2011). Recombinant 
adenoviruses have tremendous potential in both research and therapeutic applications 
(Marukawa et al., 2012). There are numerous advantages they provide when introducing 
genetic material into host cells and the permissive host cell range is very wide (Xin et al., 
2007; Naskalska et al., 2009). After entering cells, the virus remains epichromosomal – the 
adenoviral genome does not integrate into the host chromosome so does not activate or 
inactivate host genes -. Recently, recombinant adenoviruses have been used to deliver RNAi 
into cells (Nishioka et al., 2012), and are especially useful for gene transfer and protein 
expression in cell lines that have low transfection efficiency with liposome (Byrnes et al., 
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1995). The replicative and non-replicative adenovirus has been used to infect many cell types 
from mammals and chickens for high expression of the recombinant protein (Fisher and 
Watanabe, 1996; Hermening et al., 2004).  
Non-replicative adenovirus-vectored antigen delivery systems in chickens provide a 
means whereby the problems associated with modified live viruses and inactivated viruses 
can be overcome (Avakian et al., 2007). Recombinant replication-defective human 
adenoviruses (Ad), such as adenovirus type 5 (Ad5) combine a number of very promising 
properties. First, despite its human origin, vectored adenovirus is able to target foreign genes 
in a wide spectrum of animal cells with maximum efficacy, even those in which Ad5 cannot 
replicate (Ali et al., 1994). Second, the viral DNA is transiently maintained and expressed for 
several weeks to months; witch produces long lasting immunity against the foreign protein 
(Alemany et al., 2000).  
Transduction of chicken cells in vitro and in vivo by replication-defective, thus non-
spreading, adenovirus type 5 (Ad5) was reported for the first time in 1995 (Adam et al., 
1995). Human adenoviral vectors potentially transduce chicken cells through binding of the 
adenovirus fiber to the coxsackie virus and adenovirus receptor on the surface of chicken 
cells (Tan et al., 2001). More recently, chickens immunized with a single subcutaneous 
injection of an adenovirus-vectored avian influenza H5 antigen were 100% protected from an 
intranasal challenge with VN/1203/04, which proved lethal to all control-vaccinated chickens 
within 2 days (Gao et al., 2006). In addition, at least one of the human adenovirus 
components, hexon, is highly immunogenic and confers adjuvant activity to exogenous 
antigens (Molinier-Frenkel et al., 2002). 
 23
Protective humoral response against avian influenza was reported by in ovo 
vaccination with a non-replicating vectored human adenovirus (Toro et al., 2007). Delivery 
to the amniotic fluid of the embryo is highly effective because during E17-19, the embryo 
imbibes the amniotic fluid and viral particles are rapidly found in the respiratory tract and in 
the digestive system (Jochemsen and Jeurissen, 2002; Kapczynski et al., 2003), resulting in 
vaccine delivery to the mucosa-associated lymphoid tissue (MALT) as well as the bursa of 
Fabricius, the avian primary B-cell organ. Exposure to antigen drives the maturation of avian 
MALT (Jeurissen et al., 1989; Reese et al., 2006) and suggests that in ovo immunization may 
accelerate the maturation of embryonic bronchus-associated lymphoid tissue (BALT) 
(Rautenschlein and Haase, 2005). 
In ovo vaccination plays an important role in protecting chickens from several diseases 
(Josefsberg and Buckland, 2012). This injection system vaccinates up to 70,000 chicken eggs 
per hour in a more uniform and precise manner than post-hatch mass vaccination methods 
(Avakian et al., 2007). Today, approximately 90% of broiler chickens grown in the USA are 
vaccinated in ovo 2-3 days prior to hatch at the time when eggs are transferred from the 
incubator to the hatcher (Avakian et al., 2007). Commercial in ovo vaccination using 
modified live viruses is common practice for Marek’s disease (MD), infectious bursal disease 
(IBD) and fowl pox (FP). In other cases, however, in ovo compatibility has been problematic, 
as in the case of the modified live viruses for Newcastle Disease (ND) and infectious 
bronchitis (IB), because of acute pathogenic effects on the embryo (Sharma et al., 2002).  
In ovo delivery of adenovirus-vectored vaccines makes it possible to mass-administer a 
wide variety of pathogen-derived antigens, delivers high potency in a single-dose regimen, 
does not interfere with epidemiological surveys of natural infections, and is not hindered by 
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pre-existing (maternal) immunity in chickens to human adenoviruses – at least at the 
experimental level. Finally, adenovirus-vectored vaccines can be generated rapidly and mass-
produced cheaply (Avakian et al., 2007). 
Since broilers are reared with a short life span (≤ 2 months), in ovo vaccination with  
replication-defective vectored adenovirus should be able to protect the great majority of 
chickens against Cpα and significantly reduce food borne disease in human. Introduction of 
this new class of in ovo vaccination may thus provide a simple and safe means for mass 























PRODUCTION AND CHARACTERIZATION OF AGONISTIC MONOCLONAL 
ANTIBODIES AGAINST CHICKEN CD40 
 
Introduction 
As a consequence of phylogenetic separation of chickens from the reptile ancestor of 
mammals about 300 million years ago, the divergence of immune system of chicken from 
that of mammal represents an important milestone in the evolution of immune system in 
vertebrates (Furlong, 2005). Antibody-secreting B-cells are present in most jawed vertebrates, 
including chickens and mammals (Flajnik, 2002), and the diversity of B-cell receptor (BCR) 
is generated in different fashions among vertebrate species (Richards and Nelson, 2000). The 
huge diversity of BCRs of chickens and mammals are generally generated by V(D)J 
recombination and somatic hypermutation on immunoglobulin genes (Du Pasquier, 1993). 
However, V(D)J recombination only produces very limited diversity, somatic hypermutation 
/ gene conversion contribute mostly the wide spectrum diversity of BCRs in chickens 
(Thompson and Neiman, 1987). The gut-associated lymphoid tissues, such as bursa of 
Fabricius, provide another specialized environment for extra diversification stage of B-cells 
development in chickens (Withers et al., 2006). However, very little information regarding 
molecular signals for controlling development, survival, and apoptosis of chicken B-cells is 
available (Kothlow et al., 2010). 
In mammals, tumor necrosis factors (TNFs) play important roles in the development 
and regulation of the immune system, especially for B-cells (Williamson et al., 1983; Watts, 
2005). The function of each TNF is essentially determined by its interaction with receptor 
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expressed on B-cells, which belongs to tumor necrosis factor receptor (TNFR) superfamily 
(Locksley et al., 2001). The TNFR, also called death receptor, is a trimetric cytokine receptor 
for TNF. Because TNF is often used to describe TNF-α, TNFR is often used to describe the 
receptors that bind only to TNF-α, also known as CD120. The TNFR also cooperates with 
adaptor proteins like tumor necrosis factor-associated factors (TRAFs) to determine the 
outcome while it was bound by corresponding TNF (Baker and Reddy, 1998). Both 
lymphotoxin-α and TNF-α were found in the chicken, several members of the chickens 
TNF/TNFR family have also been identified, including Fas/FasL, Ox40L, Trail/TrailL, 
CD30/CD30L, and Rank/RankL (Burgess et al., 2004; Hong et al., 2006). 
However, several TNFRs can react to more than one TNF (Locksley et al., 2001; 
Hehlgans and Pfeffer, 2005). TNF family members share a low degree of sequence similarity, 
with the majority of conserved residues involved in maintaining the structure of the C-
terminal domain of TNF (Idriss and Naismith, 2000). The majority of TNF are type II 
transmembrane proteins, and reminding are mostly in secretory fashion, which may be 
cleaved from the membrane by proteases and released as soluble proteins (Tan et al., 1997). 
Recent progress has been made by cloning and expressing chicken CD40L (CD154) 
and BAFF, which belongs to TNF family members and both are essential for differentiation 
and development of chicken B-cells. Like mammal BAFF, chicken BAFF was shown to 
function as survival factor for mature peripheral B-cells (Schneider et al., 2004). CD40L has 
several essential functions in the regulation of adaptive immunity in mammals, as clearly was 
evidenced by the severe consequences of inactivating mutations in X-linked hyper IgM 
syndrome (Aruffo et al., 1993; Pearson et al., 2001). CD40L not only provides signals for the 
maturation of dendritic cells, which play critical role in the initiation of T-cell response 
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(Moodycliffe et al., 2000), but is also required for the formation of germinal centers, affinity 
maturation, and generation of class-switched memory B-cells in T-cell dependent humoral 
responses (Foy et al., 1994). Compared to the broad distribution of CD40 on cells and tissues, 
CD154 was initially reported to be expressed by activated T-cells (Armitage et al., 1992). 
The chicken CD154 was found to be expressed on both activated CD4 and CD8 T-cells, and 
larger proportion of chicken CD8 T-cells than mammalian CD8 T-cells express this molecule 
upon activation (Tregaskes et al., 2005). 
CD40, an integral membrane glycoprotein of the TNF-receptor superfamily, is 
expressed mainly on professional antigen-presenting cells (APCs), including B-cells, 
macrophages, and dendritic cells (van Kooten and Banchereau, 1997; van Kooten and 
Banchereau, 2000). As well as APcs, a variety of non-immune cells also express CD40, the 
cognate receptor for CD154, and can respond to a CD154 stimulus by secreting 
proinflammatory cytokines (Dechanet et al., 1997). However, high levels of CD40 can also 
be detected on a wide range of human cancer cells of bladder, breast, and ovary (Sabel et al., 
2000; Hill et al., 2005). The natural ligand for CD40 is CD154 (CD40L), which is transiently 
expressed on activated CD4+ T-cells (Clark and Ledbetter, 1986; Armitage et al., 1992). The 
engagement of CD154 to the CD40 receptor on APCs provides the critical signal required for 
optimal APC activation, which results in up-regulation of MHC and CD40 molecules, 
expression of CD80/86, and secretion of cytokines (Grewal and Flavell, 1996; Noelle, 1996). 
These steps are critical for optimal priming and expansion of antigen-specific effector and 
memory T-cells, B-cell response, and immunoglobulin class switching (van Kooten and 
Banchereau, 1997; Gordon and Pound, 2000). 
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Agonistic anti-CD40 antibodies/recombinant CD40L have been successfully used as 
substitutes for CD4+ T-cell help to regulate the activities of APCs both in vitro and in vivo in 
mammals and chickens (Bennett et al., 1998; Ridge et al., 1998; Tregaskes et al., 2005; 
Kothlow et al., 2008). Agonistic monoclonal antibodies (mAbs) against mouse CD40 have 
also been shown to directly mimic CD4+ T-cell help in vivo in response to T-cell dependent 
antigens (Banchereau et al., 1994; Dullforce et al., 1998; Barr and Heath, 1999; French et al., 
1999; Garcia de Vinuesa et al., 1999). Such mAbs can also confer a potent adjuvant effect 
when physically conjugated with antigen (Diehl et al., 1999; French et al., 1999; Sotomayor 
et al., 1999; Ninomiya et al., 2002; Barr et al., 2003; Barr et al., 2005; Barr et al., 2006), 
inducing protective immune responses against pathogens or tumors (Diehl et al., 1999; 
French et al., 1999; Sotomayor et al., 1999; Ninomiya et al., 2002; Hatzifoti and Heath, 
2007). 
In contrast to the extensive physico-biochemical and functional characterization of 
human and murine CD40 by use of agonistic anti-CD40 mAbs, relatively few reports are 
available on this topic in the chicken, except for two recent seminal publications by 
Tregaskes and co-workers (Tregaskes et al., 2005; Kothlow et al., 2008), who identified 
chicken CD40 (chCD40) and characterized the chCD40/chCD40L ligation using 
recombinant chCD40L. In this study, we describe for the first time the development and 
characterization of an agonistic anti-chCD40 mAb, 2C5, which, like analogous agonistic 
anti-CD40 mAbs against mammalian CD40, is functionally active when specifically bound to 
CD40 on chicken APCs, causing downstream immunological effects. MAb 2C5 stimulated 
significant nitric oxide (NO) synthesis in chicken HD11 macrophages and dramatically 
stimulated the proliferation of serum-starved chicken DT40 B-cells. 
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Materials and methods 
Cell cultures 
Cell cultures were maintained at 37oC in an atmosphere of 5% CO2. Chicken HD11 
macrophages (Crippen et al., 2003) were grown in DMEM medium (Mediatech, Manassas, 
VA) supplemented with 8% fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA) and 
5% chicken serum (Sigma, St. Louis, MO). Chicken DT40 B-cells (Winding and Berchtold, 
2001) were cultured in DMEM medium supplemented with 10% fetal bovine serum, 1% 
chicken serum, 10% tryptose phosphate broth and 50µM β-mercaptoethanol. Chicken 
primary B-cells and primary macrophages were prepared according to published protocols 
with minor modifications (Endsley et al., 2009). Briefly, the spleen was surgically removed 
from a laying hen and rinsed in ice-cold serum-free RPMI 1640 medium (Sigma) containing 
100 IU/mL of penicillin/streptomycin. The tissue was then mechanically disrupted using a 
surgical blade and a syringe plunger, and splenocytes were obtained by passing the 
preparation through a 70µm cell strainer (BD Falcon, San Jose, CA), and resuspended in 
RPMI 1640 medium supplemented with 8% fetal bovine serum, 5% chicken serum, and 25 
nM phorbol-12-myristate-13-acetate (Cell Signaling Technology, Beverly, MA). Chicken 
primary B-cells were then isolated from splenocytes by positive selection using mouse anti-
chicken Bu-1 mAb (SouthernBiotech, Birmingham, AL) as follows: after incubating 
splenocytes with Bu-1 mAb for 30 minutes at 4oC, splenocytes were washed three times with 
ice-cold sorting buffer [0.5% bovine serum albumin (BSA), 2mM ethylenediaminetetraacetic 
acid (EDTA) in phosphate buffered saline (PBS), pH 7.4], incubated with goat anti-mouse 
immunoglobulin microbeads (Miltenyi Biotech, Auburn, CA) for 30 minutes at 4oC, and 
positively selected using the AutoMACS automated magnetic cell sorter (Miltenyi Biotech). 
 30
Chicken primary macrophages were derived by culturing adherent monocytes from 
splenocytes in RPMI medium containing 8% fetal bovine serum, 5% chicken serum, and 
10µg/mL bovine insulin in a 6-well cell culture plate (Nunc, Rochester, NY) in an 
atmosphere of 5% CO2 at 37
oC for 13 days. Adherent cells were collected using Accutase 
(Sigma) and isolated by positive selection. Briefly, cells were incubated with mouse anti-
chicken MHC-II mAb (SouthernBiotech) for 30 minutes at 4oC and then washed three times 
in ice-cold sorting buffer, incubated with goat anti-mouse immunoglobulin microbeads for 30 
minutes, and positively selected using the AutoMACS automated magnetic cell sorter. 
 
Generation of recombinant extracellular domain of chicken CD40 (chCD40ED) 
Total RNA was isolated from chicken spleen using Trizol® (Invitrogen, Carlsbad, CA) 
and used for cDNA synthesis using Superscript II reverse transcriptase (Invitrogen). The 
sequence encoding chCD40ED was then amplified by nested PCR using Accuprime Pfx DNA 
polymerase (Invitrogen). Primers (inside and outside) used in this nested PCR are shown in 
Table1. The PCR product was gel-purified, ligated into the pcDNA 3.1/V5-HIS-TOPO 
vector (Invitrogen), and 5µL of the ligation reaction was used to transform Top 10 E. coli 
cells (Invitrogen). Plasmid minipreps with cDNAs encoding chCD40ED were sequenced, and 
the cDNA encoding chCD40ED was amplified by overlapping extension PCR using primers 
shown in Table 1. The forward primers (CD6chCD40 Fwd-1, CD6 Eco RV Fwd-2, and CD7 
Fwd) introduced an Eco RV restriction site (in bold) and the CD5 secretory signal sequence 
(underlined) at the 5’ terminus (Table 1). The reverse primer (cCD40 Flag Rev) introduced a 
Bam H1 restriction site (in bold) and the FLAG-tag sequence (underlined) at the 3’-terminus 
(Table 1). This construct was then sub-cloned into the eukaryotic expression vector pcDNA5 
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(Invitrogen) and the gene was confirmed by DNA sequencing. Recombinant chCD40ED (Fig. 
1) was expressed as a FLAG-tagged protein (Fig. 2) in HEK 293 Free-Style cells (Invitrogen) 
and affinity purified using anti-FLAG M2-agarose affinity chromatography (Sigma) (Hope et 
al., 2005). This chCD40ED was used for immunization of Balb/c mice for the production of 
monoclonal antibodies. 
 
Table 1. Primer sequences used in cloning of extracellular domain of chicken 
CD40 
Primer Name Direction Primer sequence 
Outside Forward 5’ – GGG TCG GAT CGG ATC GGA TGG G – 3’ 
Outside Reverse 5’ – GCT GCT CCC GTC GGA GGC – 3’ 
Inside Forward 
5’ – CAC CAT GGG GCG GCT CGG GCT GCT – 
3’ 
Inside Reverse 





5’ – ACC TTG TAC CTG CTG GGG ATG CTG 
GTC GCT TCC TGC CTC GGA CTG CAG ATG 
GTG AAT TGC TCT GAC AAG CAG – 3’ 
CD7 Fwd Forward 
5’ – ATA GAT ATC GCC AGC CAT GGC CAT 




5’ – ATA GAT ATC ACC ATG CCC ATG GGG 
TCT CTG CAA CCG CTG GCC ACC TTG TAC 




5’ – ATA GGA TCC TTA CTT ATC GTC ATC 
GTC CTT GTA GTC TGA CAG CGA TGA GCG 




Fig. 1. Amino acid sequence of CD5-chCD40ED-FLAG chimeric protein. Recombinant cDNA technology 
was used to produce chCD40ED (amino acids 27-199) linked in-frame to the sequence encoding the CD5 
secretory signal at the N-terminus (amino acids 1-26, bolded), and the FLAG-tag sequence (amino acids 
200-207, bolded italics) at the C-terminus. 
Monoclonal antibody production 
 
Monoclonal antibodies against chCD40 were produced according to previously 
published protocols used routinely (Mast et al., 1998). Briefly, four female BalB/c mice were 
injected four times subcutaneously with 50µg chCD40ED in RIBI adjuvant [1mg Lipid A, 
monophosphorylated from E. coli F583 (Sigma), 1mg Trehalose 6, 6′-dimycolate from 
Mycobacterium tuberculosis (Sigma), 0.4% (v/v) Tween-80 (Sigma), 4.5% (v/v) squalene in 
2mL MQ-water]. Mice with the best immune response against chCD40ED were activated by 
intraperitoneal injection of 50µg chCD40ED without adjuvant at three and five days prior to 
splenocyte harvest. On the day of fusion, a splenocyte suspension was prepared and fused 
with Sp2/0 myeloma cells (ATCC, Manassas, VA) by electrofusion using the Electro Cell 
Manipulator® ECM 2001 (BTX, Holliston, MA). Hybridomas were plated in 96-well cell 
culture plates (Nunc) with addition of cytokines (Berghman et al., 1992) to sustain single cell 
growth, and HAT selection was applied for seven days. Primary screening was performed by 
ELISA on day 14 post-fusion using ELISA plates coated with chCD40ED. Positive clones (27 
clones) from the primary screening were further tested by immunocytochemistry (ICC) on 
chicken DT40 B-cells and chicken HD11 macrophages. Briefly, cells were washed three 
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times with ice-cold PBS, pH 7.4, followed by fixation on poly-L-lysine coated slides using 
4% (w/v) paraformaldehyde in PBS, pH 7.4, for 10 minutes. Cells were blocked for one hour 
in 5% (w/v) BSA (Sigma) in TBST [25 mM Tris-HCl, pH 7.6, 0.15 M NaCl, 0.1% Triton X-
100 (v/v)]. Each slide was then incubated with 3mL hybridoma supernatant (27 hybridoma 
supernatants were tested separately) at room temperature for two hours, followed by 
incubation with FITC-conjugated goat anti-mouse IgG (Jackson ImmunoResearch 
Laboratories, West Grove, PA) diluted 500-fold in TBST at room temperature for one hour. 
Specific staining on cells was visualized using a Zeiss Axioplan Microscope (Zeiss, 
Hamburg, Germany) and analyzed using Axio imager software (Zeiss). Twenty-four clones 
were thus identified and agonistic clones were further selected from those ICC positive 
clones using functional assays as described below. 
 
Selection of agonistic anti-chCD40 monoclonal antibodies 
Agonistic anti-chCD40 mAbs were selected based on (1) induction of NO synthesis in 
chicken HD11 macrophages in vitro, and (2) enhancement of proliferation in serum-starved 
chicken DT40 B-cells in vitro, as described below. Out of the 24 clones that stained chicken 
DT40 B-cells and HD11 macrophages, five agonistic anti-chCD40 hybridomas were cloned 
by limiting dilution, and the most promising clone 2C5 (IgG1) was sent to Antagene Inc 
(Sunnyvale, CA) for ascites production. The isotypes of five mAbs were determined using 





Purification of anti-chCD40 mAbs 
Anti-chCD40 mAbs were purified from hybridoma supernatants or from ascites by 
Protein A Sepharose affinity chromatography. Briefly, one volume of supernatant of 
hybridoma culture or ascites fluid was diluted in eight volumes of application buffer [1.5M 
glycine, 3M NaCl in MQ-water, pH 8.9], mixed with immobilized Protein A (Thermo 
Scientific, Rockford, IL) for one hour on an end-over-end mixer. After rinsing with 
application buffer, the purified antibody was eluted with 50mM citric acid, pH 3.5 and 
dialyzed against PBS, pH 7.4. 
 
Detection of nitric oxide (NO) by the Griess assay 
To detect the concentration of NO synthesized by chicken HD11 macrophages 
stimulated by agonistic anti-chCD40 antibodies, chicken HD11 macrophages (1x106) were 
cultured in a 24-well cell culture plate in an atmosphere of 5% CO2 at 37
oC for 12 hours; the 
plates were then rinsed three times with medium to remove unattached cells, followed by 
incubation with either anti-chCD40 hybridoma supernatants (3mL) or purified anti-chCD40 
mAbs (1µg/mL) for 18 hours. A mouse IgG1 (1µg/mL) was used as a negative control. 
Nitrite concentration, a measure of NO synthesis, was assayed in 50µL of culture supernatant 
using the Griess reagent; 100µL sulfanilamide solution [1% (w/v) sulfanilamide (Sigma) in 
2.5% (v/v) phosphoric acid in MQ-water] was added to the supernatants, followed by 
addition of 100µL naphthylethylenediamine dihydrochloride solution [0.1% (w/v) 
naphthylethylenediamine dihydrochloride (Sigma) in 2.5% (v/v) phosphoric acid in MQ-
water) (Bingaman et al., 2000; Shoda et al., 2000; Shoda et al., 2001a; Shoda et al., 2001b). 
Absorbance at 550nm was compared to that of a freshly prepared NaNO2 standard curve 
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(ranging from 0 to 160µM), and was used to calculate mean micromolar concentration of 
nitrite in triplicate cultures ± SD. Accumulation of nitrite was analyzed for statistical 
significance using the t-test. Out of the 24 anti-chCD40 hybridomas that were screened, 21 
clones were found to stimulate NO production in chicken HD11 macrophages. The five best 
clones (designated as 2C5, C6, 1B5, C19, and 1G1) were then cloned by limiting dilution, 
purified by protein A Sepharose affinity chromatography, and used at four concentrations 
(0.3, 1, 3, or 10µg/mL) to assess dose-dependent NO synthesis by chicken HD11 
macrophages. 
 
B-cell proliferation assay 
To assess the capacity of the selected agonistic anti-chCD40 mAbs to stimulate 
proliferation of chicken DT40 B-cells, the minimal concentration of fetal bovine and chicken 
serum necessary for survival in chicken DT40 B-cell medium was first determined. Chicken 
DT40 B-cells were cultured in DMEM medium supplemented with 0.156% (v/v) fetal bovine 
serum, 0.0156% (v/v) chicken serum, 10% (v/v) tryptose phosphate broth and 50µM β-
mercaptoethanol. Each well of a 24-well cell culture plate was seeded with chicken DT40 B-
cells (5x105) in an atmosphere of 5% CO2 at 37
oC, with addition of either one of the five 
different purified agonistic anti-chCD40 mAbs at 1µg/mL, or mouse IgG1 (1µg/mL) as a 
negative control. Cell densities (mean cell number counts per 24 hours in triplicate cultures ± 
SD) were determined at 24, 48, and 72 hours after the addition of the mAbs. Cellular 
proliferation (as assessed by the trypan blue exclusion test) was analyzed for statistical 
significance by the Mann-Whitney test. Dose-dependent B-cell proliferation was further 
tested at four concentrations: 0.3, 1, 3, or 10µg/mL. 
 36
Flow cytometric assay 
Fc receptors on cells (DT40 B-cells, HD11 macrophages, primary chicken B-cells, and 
primary chicken macrophages) were blocked with purified mouse immunoglobulin at 
200µg/ml for 30 minutes at 4oC prior to staining, and Zenon labeling technology (Invitrogen) 
was used for labeling 2C5 (or mouse IgG1) with R-Phycoerythrin per the manufacturer’s 
instructions. Briefly, cells (1 x 105) were incubated with various dilutions of R-
Phycoerythrin-labeled 2C5 for 30 minutes at 4oC, followed by fixation with 2% 
formaldehyde in PBS, pH 7.4, Flow cytometric analysis was performed using FACSCalibur 




Chicken DT40 B-cells or chicken HD11 macrophages (1x108) were washed three 
times with ice-cold PBS and then incubated in 2mL of ice-cold lysis buffer [1% Triton X-100 
(v/v), 150mM NaCl, 50mM Tris base, pH 8.0], supplemented with HaltTM protease and 
phosphatase inhibitor cocktail (Thermo Scientific) for 30 minutes on ice. After centrifugation 
at 16,000 x g for 15 minutes, the supernatant was collected and pre-cleared by incubation 
with 100µL protein G agarose (Thermo Scientific) and 20µg purified mouse IgG (Jackson 
ImmunoResearch) for one hour to reduce nonspecific binding. Mouse IgG and protein G 
agarose were removed by centrifugation at 10,000 x g for five minutes. A pool of agonistic 
anti-chCD40 mAbs was prepared by mixing 4µg of each of the five purified agonistic mAbs 
(2C5, C6, 1B5, C19, and 1G1). Lysates were immunoprecipitated with this mAb pool and 
100µL protein G agarose (Thermo Scientific) for two hours at 4oC on an end-over-end mixer. 
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Immune complexes were collected by centrifugation, washed three times with ice-cold lysis 
buffer, and then boiled for 10 minutes at 95oC in 50µL 1X Laemmli sample buffer containing 
50mM fresh dithiothreitol (Bio-Rad, Hercules, CA) and 5% 2-mercaptoethanol. 
Iodoacetamide was then added to a final concentration of 25mM and immune complexes 
were separated by SDS-PAGE and identified by Western blotting. 
 
Western blotting 
Samples were separated by SDS-PAGE using a 10% PreciseTM protein gel (Thermo 
Scientific) under reducing conditions, and then transferred to a PVDF membrane (Bio-Rad) 
for 90 minutes at 40V in transfer buffer [25mM Tris, 192mM glycine in 800mL Milli-Q 
water and 200mL methanol]. Twenty µg reduced mouse IgG1 and 5µg BSA were used as the 
negative control. The membrane was blocked overnight in 5% skimmed milk (BD) in TBST 
[TBS containing 0.1% Tween-20 (v/v)], and then incubated with polyclonal mouse anti-
chCD40 antibody diluted at 1:5000 in TBST containing 5% skimmed milk at room 
temperature for two hours. This was followed by incubation with the TrueBlot system 
(eBiosciences, San Diego, CA) in TBST containing 5% (w/v) skimmed milk at room 
temperature for one hour. This system includes a horseradish peroxidase (HRP)-conjugated 
antibody that is specific for native mouse IgG, thus eliminating the interference of IgG 
present in the purified immune complexes. The resulting bands on the membrane were 
developed using ECL Plus developer system (GE Healthcare, Foster City, CA), visualized 




Results and discussion 
The CD40/CD40L signaling pathway is crucial in humoral and cell-mediated 
immunity in mammals and chickens. The primary structures of chCD40 and chCD40L were 
recently identified, and chCD40-chCD40L interaction was shown to induce NO synthesis in 
the chicken HD11 macrophage cell line and to support the proliferation of splenic B-cells 
(Tregaskes et al., 2005; Kothlow et al., 2008). To investigate the distribution and the 
biological function of chCD40, a novel agonistic anti-chCD40 mAb 2C5 was produced and 
characterized in this study. 
To obtain recombinant chCD40ED, a DNA construct encoding the extracellular domain 
of chicken CD40 linked in-frame to the sequence encoding the CD5 secretory signal 
sequence at the 5’ terminus, and the sequence encoding the FLAG-tag at the 3’ terminus, was 
generated in the eukaryotic expression vector pcDNA5. Protein                                                                
expressed by the resultant construct, designated as chCD40ED-FLAG, was verified in HEK 
293A cells by immunocytochemistry (Fig. 2), whereas HEK 293 Free-Style cells (Invitrogen) 
were used to generate large amounts of recombinant FLAG-tagged chCD40ED that was 
affinity purified using anti-FLAG M2-agarose gel (Sigma). This protein preparation was used 
for immunization of Balb/c mice for the production of monoclonal antibodies. 
A large number of hybridomas were obtained two weeks following electrofusion of 
splenocytes from hyper-immunized mice with Sp2/0 myeloma cells. Antibodies recognizing 
chCD40ED were secreted by 27 different hybridomas as identified by ELISA. Twenty four 
out of these 27 hybridomas secreted antibodies that also bound to native CD40 on the surface 
of chicken DT40 B-cells and HD11 macrophages, as determined by ICC (Fig. 3). No positive 
staining was observed in the negative control (mouse IgG1). 
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Fig. 2. Expression of chCD40ED-FLAG in HEK 293A cells transfected with pcDNA5-(CD5-chCD40ED-
FLAG). 48 hours post transfection, expression of chCD40ED-FLAG in transfected HEK 293A cells were 
visualized by red alkaline phosphatase (AP) staining (AP conjugated anti-FLAG mAb). 
 
  
Fig. 3. Immunocytochemical detection of CD40 expressed on chicken DT40 B-cells (A) and chicken HD11 
macrophages (B) stained with undiluted culture supernatant of anti-chCD40 hybridoma 2C5. Cells were 
fixed on poly-L-lysine coated slides using 4% paraformaldehyde in PBS, pH 7.4. FITC-conjugated goat 
anti-mouse IgG was used for detection. 
 
In order to characterize 2C5 and facilitate its further use, the class and subclass 
identities of 2C5 were determined. Wells with the highest response [highest A(450)] indicate 
A B 
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isotype and light chain composition. 2C5 clearly have positive responses in IgG1 (heavy-
chain identification) and κ (light-chain identification) (Fig. 4). 
The binding of 2C5 to CD40 on the cell surface of chicken cells was confirmed in vivo 
by flow cytometry on chicken DT40 and HD11 cells (Fig. 5A and 5B), and with primary B-
cells and macrophages (Fig. 5C and 5D). Pre-immune mouse IgG1 was used as the negative 
control. Primary chicken B-cells that had been selected with mouse anti-chicken Bu-1 mAb 
expressed high levels of CD40. Primary chicken macrophages differentiated from attached 
spleen monocytes were purified by mouse anti-chicken MHC-II mAb affinity 
chromatography (Fig. 6). 
First, specific binding of 2C5 to CD40 on chicken APCs was demonstrated by 
immunocytochemistry. CD40 expression on chicken DT40 B-cells, HD11 macrophages, 
primary macrophages, and primary B-cells were confirmed by flow cytometry, indicating 
that 2C5 can be used for detailed screening of the expression level and distribution of 
chCD40 on various chicken cells and tissues. This expression profile confirms what was 
reported in studies that used recombinant chCD40L instead of an immunochemical reagent 
(Tregaskes et al., 2005). 
Flow cytometric analysis showed that primary macrophages did express CD40, but at lower 
levels than primary B-cells (Fig. 5C and 5D). Specific binding of anti-chCD40 mAb to 
chCD40 was also further confirmed in vitro by immunoprecipitation (Fig. 7). From cellular 
extracts of both chicken DT40 B-cells and HD11 macrophages, a pool of agonistic anti-






Fig. 4. Immunoglobulin isotyping on both heavy chain (A) and light chain (B) of agonistic anti-chCD40 
mAb 2C5. ELISA plates were coated with goat anti-mouse immunoglobulin antibody (5µg/mL) and then 
incubated with agonistic anti-chCD40 2C5 ascites diluted in PBS (1:1000) followed by isotype antibodies 
from rabbit. Data are average values from three samples and are representative of three independent 
experiments. (A) Reactivity of heavy chain isotype antibodies to 2C5. Significant IgG1 response to 2C5 
was detected. (B) Reactivity of light chain isotype antibodies to 2C5. Significant κ response to 2C5 was 







Fig. 5. Flow cytometric assessment of the expression of CD40 on chicken DT40 B-cells, chicken HD11 
macrophages, Bu-1 positive chicken primary B-cells, and MHC-II positive chicken primary macrophages 
(A to D, respectively). Distribution of fluorescence intensities of cells stained with 5µg of either R-
Phycoerythrin-labeled 2C5 (red) or R-Phycoerythrin-labeled mouse IgG1 (blue) per one hundred 








Fig. 6. Morphology of chicken primary macrophages derived from peripheral blood mononuclear cells 
following Giemsa staining (Figure A and B). Chicken primary macrophages were derived by culture of 
adherent monocytes isolated from the spleen of a laying hen. This procedure regularly yielded >90% 
primary macrophages as determined by morphology with Giemsa staining (Nissen-Druey and Speck, 
1978; Ramirez et al., 1991). Adherent cells on one 4-chamber slide (Nunc) were fixed by the addition of 
methanol for 10 minutes, and then stained with 1:50 diluted Giemsa stain solution (Sigma). The diameter 
of the large cell (right) is 70 µm. 
 
Despite the specific binding of 2C5 to chCD40, chCD40 could not be 
immunoprecipitated by 2C5 alone. Although the reason for this failure is not entirely clear at 
present, one possible explanation is that 2C5 may recognize a conformational epitope on 
chCD40 that is lost upon release of CD40 from the APC cell membrane during the lysis 
protocol preceding the antigen-antibody interaction. This hypothesis is corroborated by the 
fact that chCD40 was not detected by 2C5 in Western blotting under reducing SDS-PAGE. 
By contrast, chCD40 was successfully immunoprecipitated by a pool of five specific anti-





Fig. 7. Immunoprecipitation of chicken CD40 followed by detection with polyclonal anti-chCD40 
antiserum by immunoblotting. Chicken CD40 was immunoprecipitated from total cell lysates from 
chicken DT40 B-cells (lane A) or HD11 macrophages (lane B) using a pool of five agonistic anti-chCD40 
mAbs. SDS-PAGE was performed after addition of 25mM of iodoacetamide to the eluted proteins 
followed by Western blotting. BSA (lane C) and reduced mouse IgG1 (lane D) were used as the negative 
controls. The membrane was probed with polyclonal antibody raised against the extracellular domain of 
chicken CD40 followed by (HRP)-conjugated anti-mouse IgG secondary antibody, and visualized with 
the ECL detection system. In this particular experiment, we used the TrueBlot system (eBioscience) to 
eliminate the interference by immunoglobulin heavy and light chains originating from the isolated 
immune complex.   
 
Reducing SDS-PAGE analysis of immunoprecipitated chCD40 from cell lysates 
showed two bands of 55kDa and 32kDa. Chicken CD40 amino acid backbone accounts for a 
mass of 30kDa (accession number: Q9DDD2). The extracellular domain of chCD40 consists 
of 173 residues (43% identity with the extracellular domain of human CD40), including 20 
cysteines and three potential N-linked glycosylation sites (Asn25, Asn52, Asn96) (one more 
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than in human CD40). The discrepancy between the apparent molecular weight demonstrated 
by SDS-PAGE and the predicted protein mass suggests a carbohydrate content of 
approximately 41%, likely due to N-linked glycosylation. A similar discrepancy was 
observed in human CD40 (predicted protein mass = 28.3 kDa vs. an apparent molecular 
weight of 47 kDa estimated by SDS-PAGE) (Paulie et al., 1984; Clark and Ledbetter, 1986; 
Braesch-Andersen et al., 1989) and was demonstrated to be due to N-linked glycosylation 
(Braesch-Andersen et al., 1989). 
In mammals, agonistic mAbs against CD40 can mimic the effects of CD40L on B-cells 
in vitro (Barr et al., 2003). In this study, agonistic activity of 2C5 was demonstrated by 
induction of NO synthesis in chicken HD11 macrophages and significant proliferation of 
serum-starved chicken DT40 B-cells, properties that are shared with chCD40L (Tregaskes et 
al., 2005; Kothlow et al., 2008). The biological effects of anti-chCD40 mAbs were examined 
in two different in vitro assays: NO synthesis in chicken HD11 macrophages (Tregaskes et 
al., 2005), and proliferation of serum-starved chicken DT40 B-cells. Anti-chCD40 antibodies 
from 21 out of 24 anti-chCD40 hybridoma supernatants were capable of stimulating 
significant NO synthesis in chicken HD11 macrophages. The five best agonistic anti-chCD40 
hybridomas were then cloned by limiting dilution. Agonistic anti-chCD40 mAbs secreted 
from these five clones were purified and used in another round of nitrite detection assays. No 
detectable NO synthesis was observed by stimulation with mouse IgG1 (1µg/mL), in contrast 
to all five agonistic mAbs. The mAb designated 2C5 elicited a dose-response NO synthesis 
in chicken HD11 macrophages with maximal activity at 10µg/mL (Fig. 8A). This mAb was 
therefore selected for all subsequent assays. CD40 signaling has also been shown to enhance 
survival and proliferation of chicken DT40 B-cells (Tregaskes et al., 2005). Here we 
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demonstrated that stimulation of serum-starved chicken DT40 B-cells by 2C5 - in the 
absence of IL-4 – does result in significant B-cell proliferation (Fig. 8B and 8C) (P<0.001), 
while similar concentrations of control mouse IgG1 had no effect on cell growth.  A dose-
response relationship was observed with 2C5 doses between 1µg/mL and 10µg/mL. At 
1µg/mL, DT40 B-cell densities had increased from the initial seeding density (~5x106) to 
~6x106 within the first 24 hours. 
The activation of chicken HD11 macrophages and chicken DT-40 B-cells at a low 
concentration (1µg/mL) of 2C5 was shown to occur via the specific binding of this agonistic 
antibody to CD40 on the cell surface, since control mouse IgG1 had no such effect. In 
addition to the strong survival promoting activity, the signal delivered by 2C5 was sufficient 
to induce vigorous proliferation of serum starved chicken DT40 cells in the absence of 
antigen or cytokines like IL-4. In contrast, mammalian B-cell proliferation stimulated by the 
cross-linking of CD40 with agonistic anti-CD40 needed the co-stimulation of IL-4 (Clark and 











Fig. 8. Agonistic effects of 2C5. A. The vertical axis shows the concentration of NO produced in 
supernatants from chicken HD11 macrophages stimulated by serial three-fold dilutions of purified anti-
chCD40 mAb 2C5 (solid squares), negative isotype control mouse IgG1 (solid circles), or negative control 
PBS (solid triangles). B. Enhanced proliferation in serum-starved chicken DT40 cells as a function of 
time. The vertical axis shows the cell density (cells/mL) of live chicken DT40 cells incubated in the 
presence of 5µg/mL of purified anti-chCD40 mAb 2C5 (solid squares) or negative control mouse IgG1 
(solid circles) after 24, 48, and 72 hours. C. Enhanced proliferation of serum-starved chicken DT40 cells 
as a function of 2C5 concentration. The vertical axis shows the cell density (cells/mL) of live chicken 
DT40 cells incubated in the presence of serial three-fold dilutions of 2C5 or control mouse IgG1 for 24, 48, 
and 72 hours. Values are means of triplicate observations ± SD; n=3; *=P<0.05; **=P<0.01; ***=P<0.001 
 
Stimulation of B-cells and activation of APCs such as macrophages by 2C5 is a 
valuable asset with regard to its potential use in vaccine development for chickens (Barr et al., 
2003; Barr et al., 2005; Hatzifoti and Heath, 2007). Barr and co-workers reported that the 
adjuvant effect of anti-CD40 mAb can be attributed to binding of the antibody to the CD40L-
binding domains of CD40 and is mediated by simple direct targeting and stimulation of B-




2003). The anti-CD40 mAb-based adjuvant action is extremely potent and may avoid the 
inflammatory side effects induced by most classical adjuvants (Gendelman et al., 2005; Barr 
et al., 2006; Hamzah et al., 2008). In mammals, agonistic anti-CD40 mAbs, in combination 
with Toll-like receptor agonists, have also been reported to activate cell-mediated immunity 
(Jabara et al., 1990; Schwabe et al., 1997; Khalil and Vonderheide, 2007), since antigen-
specific CD8+ T-cells can be elicited by the combination of Toll-like receptor (TLR) agonists 
and agonistic anti-CD40 mAb (Ahonen et al., 2004; Barr et al., 2005). This approach may 
provide a useful strategy in the development of novel vaccines against avian as well as 
mammalian pathogens. The identification of this potent activator of both chicken 
macrophages and B-cells will be useful in the further study of CD40L/CD40 interactions in 
the chicken.  
Taken together, the binding to CD40 on chicken cells and the stimulation of biological 
activities leads to the conclusion that 2C5 is functionally equivalent to chCD40L as described 
by Tregaskes and co-workers (Tregaskes et al., 2005; Kothlow et al., 2008). The 
identification of chCD40 by 2C5 further allowed investigation of the chicken CD40L/CD40 











PROOF OF CONCEPT: IN VIVO TARGETING A PEPTIDE TO CHICKEN CD40 
 
Introduction 
For over a hundred years, we have known that immunized hens transfer IgG from 
serum to egg yolk, but this alternative possibility of producing antigen-specific IgG in yolk 
has only attracted attention from last decades (Gassmann et al., 1990). The main advantage 
of producing antibodies in chicken eggs is the convenient acquisition of abundant amounts of 
antigen-specific IgG (>1g per week) without venipuncture (Svendsen Bollen et al., 1996). 
Yolk is an excellent and easily accessible source of IgG, and fewer resources are required for 
collecting eggs than for bleeding animals (Tan et al., 2012). As a consequence of 
phylogenetic separation of chickens from the reptile ancestor of mammals about 300 million 
years ago, many studies have indicated that chicken antibodies recognize more epitopes, 
especially highly conserved proteins, than mammalian antibodies (Camenisch et al., 1999). 
In many solid phase immunoassays, using chicken antibodies can effectively increase 
detection accuracy because they neither interact with mammalian rheumatoid factors nor 
activate mammalian complement systems, which can greatly reduce the possibility of false 
positive results or interference from complement components (Larsson et al., 1993). 
Furthermore, chicken antibodies do not react with protein A/G and exhibit low cross-
reactivity with mammalian antibodies because of their structural differences. This eliminates 
unwanted reactions in immunological assays, especially sandwich type immunoassays 
utilizing anti-species antibodies (Larsson et al., 1992).  
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Although short peptides congenitally suffer from a serious general drawback of low 
immunogenicity, chickens immunized with peptide-carrier conjugate still produce antibodies 
that recognize the corresponding native epitopes (Nagase et al., 1979). Immunization of 
chickens with a peptide-carrier conjugate is usually carried out by repeated intramuscular 
injection in each of the breast muscles with the antigen emulsified in complete Freund’s 
adjuvant or precipitated in alum (Gassmann et al., 1990; Ohta et al., 2009). However, 
antigen-specific IgG response can only be observed three weeks after the first priming, and 
maintenance of high IgG titer still requires repeated boosts. To elicit a quick and strong 
specific IgG response in chickens against peptide antigens, the use of more potent 
immunological adjuvants is considered one of the most promising ways among current 
immunization strategies (Capua et al., 2003). Many methods for improving and speeding 
antibody responses against injected antigen have been evaluated in mammals. One method is 
to target the antigen directly to antigen presenting cells (APCs) through the use of antibody 
or chemokine in vivo (Berry et al., 2003; Hatzifoti and Heath, 2007; Behzad et al., 2012). 
Agonistic antibodies against CD40 have great potential as immunological adjuvants. Without 
the use of carrier protein, recent research has shown that administration of agonistic anti-
CD40 monoclonal antibodies conjugated with peptide/hapten can induce strong and specific 
antibody responses in mammals (Hatzifoti and Heath, 2007). In previous chapter, the cross-
linking of CD40 expressed on the surface of chicken APCs with agonistic anti-chicken CD40 
mAb 2C5 was able to activate their functional status (Chen et al., 2010). In this chapter, 
chCD40 targeting of a synthetic short peptide as a method for rapid production of peptide-
specific and isotype-switched chicken IgG was evaluated. This study was designed as a 
proof-of-concept battery cage study with Leghorn chickens reared until seven weeks of age. 
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The generation of rapid and isotype-switched antibody responses by in vivo APC targeting in 
chickens should facilitate producing antigen-specific IgG in eggs. 
 
Materials and methods 
Streptavidin mediated complexing of peptide to mouse antibody 
The antibody-peptide complex used for chicken immunization was prepared by 
utilizing the specific interaction of biotin with streptavidin as illustrated in Fig. 9. A synthetic 
peptide, NAWSKEYARGFAKTGK, with addition of biotin on the amino-terminus of N 
residue was commercially obtained (GenScript Inc., Piscataway, NJ). Streptavidin (SA) 
(Thermo Scientific) was used for a controlled complexing of biotinylated peptide to 
biotinylated mouse antibody (MIg). 2C5 was purified from ascites fluid by protein G 
immunoaffinity chromatography. To prepare biotinylated MIgs, the cis-glycol groups of 
carbohydrates on the Fc region of MIg were oxidized by periodate to form reactive aldehyde 
groups, which were then actively linked to the hydrazide activated biotin. Briefly, 2C5 or 
control MIg was dialyzed against oxidation buffer (0.1M sodium acetate, pH 5.5) at 4oC 
overnight, and one part (v/v) MIg in oxidation buffer was then incubated with one part (v/v) 
oxidation buffer containing 20mM sodium meta-periodate (Thermo Scientific) at room 
temperature for 30 minutes. The reacted MIg was then dialyzed against coupling buffer 
(0.1M sodium phosphate, 0.15M NaCl, pH 7.2) to remove excess periodate. The direct 
biotinylation on the Fc region of MIg was then achieved by incubating nine parts (v/v) of the 
oxidized and buffer-exchanged MIg solution with one part (v/v) of freshly prepared 50mM 
EZ-Link® Biotin-LC-Hydrazide (Thermo Scientific) in dimethyl sulfoxide. This reaction 
was allowed to proceed for two hours at room temperature. Biotinylated MIg was separated 
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from non-reacted material by dialysis against phosphate buffered saline (PBS), pH 7.4. To 
produce SA-MIg complex, SA was incubated with biotinylated MIg at molecular ratio of 1:2 
in PBS while stirring at 4oC for three hours. The SA-MIg complex was then further incubated 
with biotin-peptide at molecular ratio of 1:2 in PBS while stirring at 4oC for three hours. The 
MIg-SA-peptide complex was sterile filtered and stored at 4oC until used. The incorporation 
of all necessary components in the final complex and stoichiometric ratio of the complex 
formation were evaluated by matrix-assisted laser desorption/ionization in the Laboratory for 
Biological Mass Spectrometry at Texas A&M University. The antigen-binding capacity of 
the 2C5-peptide complex was tested for binding to the rchCD40ED by ELISA 
 
 
Fig. 9. Preparation of antibody-peptide complex utilizing specific biotin-streptavidin interaction. (I): 
Biotinylation was limited to the carbohydrate groups on the Fc region of MIg, hence without interfering 
with antigen-antibody interaction. (II): Streptavidin (SA) was used for controlled complexing of 
biotinylated peptide with biotinylated MIg. Mab 2C5 in the 2C5-SA-peptide complex retains biological 




Administration of mAb 2C5-peptide complex on chickens 
The conditions for animal use here were approved by the Institutional Animal Care and 
Use Committee of Texas A&M University, in accordance with the guidelines of the 
American Association for Laboratory Animal Science. Five-week old Leghorn chickens were 
wing-banded and then randomly allocated to different groups (n=7). Chickens were 
immunized subcutaneously (s.c.) in the nape of the neck with 2C5-peptide complex or 
MIgG-peptide complex control at three dose levels (10µg, 30µg, and 90µg) in a volume of 
0.5ml emulsified PBS [5% (v/v) squalene, 0.4% (v/v) Tween 80 (SIGMA) in PBS)] per 
chicken. In addition, groups of chickens were immunized s.c. with SA-peptide complex 
(omission of the antibody component). Finally, one experiment involved comparison of 
adjuvant effect of 2C5 and alum. Finally, three groups of chickens (n=7) were immunized s.c. 
with three dose levels (1.5µg, 4.5µg, and 13.5µg) of SA-peptide complex precipitated in 
Imject Alum Adjuvant (Thermo Scientific). Serum samples were collected from the wing 
vein on days 4, 7, 10, and 14 post-immunization (p.i.) for determination of peptide-specific 
IgG responses by ELISA. 
 
Quantification of peptide-specific serum IgG in by ELISA 
Serum levels of peptide-specific IgG were determined by ELISA. First, biotin-peptide 
was incubated with goat anti-biotin antibody (Thermo Scientific) on a rotator at 37oC for one 
hour. Flat-bottom, 96-well microtiter plates (Thermo Scientific) were coated with peptide-
goat antibody complex (5µg/mL) in 0.05M carbonate-bicarbonate buffer, pH 9.6, overnight 
at 4oC. Supernatants containing unadsorbed peptide-goat antibody complex were removed, 
and plates were blocked with PBS containing 5% (w/v) bovine serum albumin (BSA) 
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(Rockland Immunochemicals Inc., Gilbertsville, PA) for one hour at 37oC. Peptide-goat 
antibody coated wells were washed with PBS containing 0.2% (v/v) Tween 20 (SIGMA) 
(PBST) and then incubated with chicken serum samples diluted (1:100) in PBST containing 
3% (w/v) BSA overnight at 4oC. The plates were then washed as described above and 
incubated with horseradish peroxidase conjugated rabbit anti-chicken IgY (H+L) (Thermo 
Scientific) diluted (1:12,000) in PBST containing 3% (w/v) BSA for one hour at room 
temperature. The color reaction was developed by using OptEIA™ TMB substrate (BD) per 
the manufacturer’s instructions, and terminated by addition of 1N sulfuric acid. Absorbances 
at 450 nm [A(450)] were measured in a Wallac plate reader (PerkinElmer Inc., Waltham, 
MA). The presence of peptide-specific IgG was determined by relating the mean A(450) 
value of each serum sample to that of the chicken peptide positive control serum (1:100). The 
relative levels of peptide-specific IgG in all serum samples were determined and normalized 
by calculating the sample to positive (S/P) ratio as follows: S/P value = (Sample mean - 
negative control mean)/(Peptide positive control mean - negative control mean). Comparison 
of means of S/P values was performed using one-way analysis of variance (ANOVA) with 
least significant difference (L.S.D.) as multiple comparison tests. Student’s t-test was used to 
determine significant differences in means of S/P values between treatments across all groups, 
and S/P values of the SA-peptide complex group were used as baseline. All data were 
analyzed and generated using JMP® version 9 software (SAS Institute Inc., Cary, NC). 





Results and discussion 
Mammals immunized with conjugates of agonistic anti-CD40 mAb and peptides 
produce enhanced antigen-specific antibody responses, manifested by high titer, affinity 
matured, and isotype-switched antibody in serum (Berry et al., 2003; Hatzifoti and Heath, 
2007). Utilizing these strategies for facilitating the rapid production of such highly desirable 
antibody responses in chickens has not been previously investigated. In chapter I, we have 
shown that administration of 2C5 mimicked the effects of CD4 T-cell help, enabling direct 
activation on chicken APCs in vitro, even in the absence of cytokine (Chen et al., 2010). 
The recombinant streptavidin was used as the carrier moiety and complexed to 
biotinylated 2C5 / biotinylated peptide. A controlled complexing was mediated using specific 
interaction of biotin and streptavidin. Complexing efficiency was evaluated by a shift in 
molecular weight of the streptavidin on SDS-PAGE gels and confirmed using mass 
spectroscopy. The average molecular weight of streptavidin with empty complexing groups 
was about 53 kDa, and the size shifted to 57 kDa at average as predicted while two 
biotinylated peptides (2.1 kDa) were bound to streptavidin (Fig. 10). We estimate that the 
average valence of biotinylated peptide bound to one streptavidin is approximately two and 
this 2(peptide)-streptavidin complex still have two binding sites for biotinylated mouse 
immunoglobulins. 
In order to assess functional integrity of CD40 binding, binding to chCD40 of mAb 
2C5-peptide complex was assessed by ELISA. Complex, bound to chCD40 was detected 
using anti-SA antibody (SIGMA). ELISA readout indicated that specific chCD40 binding 




Fig. 10. Overlay of the streptavidin-biotinylated peptide complex analyzed in mass spectroscopy. The 
upper line represents the streptavidin in PBS but without biotinylated peptide attachment. The lower line 
represents the complex that is composed of one streptavidin and two biotinylated peptide. 
 
To evaluate the adjuvant effect of 2C5, groups of five-week old chickens were 
immunized once s.c. with 10µg, 30µg, or 90µg mAb 2C5-peptide complex, and compared 
with the various control groups. Additional groups of chickens received same doses of SA-
peptide complex precipitated in alum or dissolved in emulsified PBS. Serum samples were 
collected from all immunized chickens at day 4, 7, 10, and 14 p.i.., and peptide-specific IgG 
response was assessed by ELISA. As shown in Fig. 11, 2C5 significantly (P<0.001) 
enhanced peptide-specific IgG responses compared to controls 4 days p.i... While the general 
profile of the peptide-specific IgG response was the same with the three doses tested, the 
30µg dose of mAb 2C5-peptide complex produced the optimal response in terms of 
magnitude and duration. Interestingly, the response was not improved by increasing the dose 
to 90µg. 
A lower quantity (10µg) of mAb 2C5-peptide complex was sufficient to elicit 
significant (P < 0.001) peptide-specific antibody response. By contrast, no peptide-specific 
IgG response was found in chickens immunized with either SA-peptide complex in 
emulsified PBS or precipitated in alum (Fig. 11). This is consistent with other studies, which 
reveal the superiority of chicken CD154 compared to alum adjuvants (Pose et al., 2011). 
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Moreover, low immune response has been reported in chickens using alum as adjuvant at 
early stages (Murthy et al., 2007). The undetectable immune response when using alum could 






Fig. 11. Peptide specific IgG response elicited by 2C5 as adjuvant determined by ELISA. Groups of seven 
5-week-old male Leghorn chickens were subcutaneously vaccinated once with 10µg (A), 30µg (B), or 90µg 
(C) mAb 2C5-peptide complex or controls. To compare the adjuvant effect of 2C5 and alum, serum 
samples were collected from chickens immunized (once, s.c.) with the same amount of SA-peptide 
complex in emulsified PBS or precipitated in alum, and peptide-specific IgG response was assessed by 
ELISA. In each case, error bars represent standard deviations from the mean and the asterisks represent 
statistical significance (n=7; *P<0.05; **P<0.01; ***P<0.001) compared with SA-peptide complex 
controls as determined by Student’s t-test. 
 
Generally, 10–100µg protein antigen emulsified/precipitated in adjuvant is usually 
applied intramuscularly in the breast muscle at two or three injection sites of 7 to 8-week-old 
chickens, and at least 2µg antigen are needed to induce significant antibody responses in five 




was sufficient to elicit significant (P<0.001) peptide-specific IgG response in this study. This 
is in clear contrast the slow, short-lived IgM response obtained with classical adjuvants 
(Cornelissen et al., 2010; Liu et al., 2011). The adjuvant effect of 2C5 was found to be 
substantially more potent than the commonly used alum. 
Since accelerated, enhanced, isotype-switched IgG response against peptide was only 
found in chickens immunized with mAb 2C5-peptide complex, the activation on APCs, 
especially peptide-specific B-cells, is attributed to CD40 targeting, not to danger-associated 
molecular patterns through Fc receptor positive cells. Besides the direct activation on B-cells, 
the adjuvant effect of 2C5 may also include promotion of antigen presentation of APCs and 
boosting of CD4+ T-cell help. We conclude that this enhanced immunogenicity is due to the 
engagement of 2C5 with CD40 on APCs in vivo, by which directly activates peptide specific 
B-cells. In the meantime, this engagement of CD40 with the 2C5 portion in the mAb 2C5-
peptide complex may also be facilitated on peptide-specific B-cells while peptide-specific 
BCR on their surface held the complex at the same time. Our results are in accordance with 
previous observations where chickens were immunized with CD154-antigen chimeric protein, 
and seen to be the result of an improved antigen presentation and boosting of CD4+ T-cell 
help, which plays a direct role in modulating B-cell response (Sanchez Ramos et al., 2011). 
This effect may be related to a better employ of this peptide by enhancing the engagement of 
2C5 on the complex for B-cell activation simultaneously with CD40 on the surface of 
peptide-activated B-cells to induce the peptide-specific IgG response (Li, 2005). Our results 
also suggest that the mAb 2C5-peptide complex may react with APCs immediately at the 
injection site after inoculation, because no visible lesion was found on the injection site 
within two weeks PI. For the concern of animal welfare, 2C5 can be considered as a safe 
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adjuvant for chicken and Freund’s adjuvant is no more needed, Freund’s adjuvant is still the 
gold standard though. 
Here we need to argue the versatility of this approach. By directional biotinylation on 
carbohydrate group on Fc region of antibodies, the binding of SA to biotin can only occur on 
Fc region of antibodies. This interaction does not affect the specific binding of chCD40 to 
2C5 on mAb 2C5-peptide complex, and interactions of Fc fragment of 2C5 with Fc receptor 
positive cells may also be avoided. Biotinylation is easy (a myriad of reagents commercially 
available), fast and causes minimal chemical changes in the hapten. Every possible 
biomolecule can be easily biotinylated, thus simple mixing with the mAb 2C5-SA complex 
makes the immunogen ready for injection. Since chicken antibodies tend to recognize more 
epitopes than mammalian antibodies, our in vivo APCs targeting strategy can clearly be 
useful for most T-dependent antigens.  Because of the highly efficient and easy complexing 
technology reported here, T-independent antigens like carbohydrates, steroids or nucleotides 
should also be applied in this system just by the addition of biotin for a controlled 
complexing. This is especially important when production of antibodies against highly 
conserved mammalian proteins, such as prions, is needed. Since chicken mucosal tissues are 
rich in APCs, we also expect this 2C5 based biological complex to induce efficient systemic 
and mucosal immune responses through the mucosal immunization route. Here we conclude 
that in vivo CD40 targeting antigen on APCs can enhance the immunogenicity of synthetic 
peptides, and can be an effective method for the rapid production of IgG in yolk.  
This study has facilitated the design of approaches to apply anti-chCD40 mAb while it 
attempts to improve the effects of subunit vaccines against a variety of chicken diseases. 
However, CD40 is not the only pathway to activate B-cells in chickens (Hobbs et al., 2006; 
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Stupar and Peterson, 2006; Totlani and Peterson, 2006). Other soluble costimulatory 
molecules, like another TNF ligand superfamily member (chBAFF) (Schneider et al., 2004), 
cytokines (chIL-4) (Peterson and Urquhart, 2006), chemokines (chIL-8) (Krumholz et al., 
2006), dendritic cell marker (CCR7) (Wu et al., 2011) are also reported to be necessary for 
B-cell activation, isotype switching, or formation of memory B-cells, thereby are good 
candidates for the enhancement of synergistic effect with CD40 to activate B-cells. Agonistic 
anti-CD40 mAbs that were in combination with Toll-like receptor agonists have also been 
reported to activate antigen specific cell-mediated immunity (Peterson et al., 2006b; Shi et al., 
2006). Hence, to maximize the synergistic effects on B- and T-cell immunity for chickens 
against pathogens, combination of these soluble mediators with agonistic anti-chCD40 mAbs 
offers practical advantages in current immunization programs for the poultry industry.  
The poultry industry is in urgent need of one-shot vaccines because it helps to save 
budget on labor fees and labor costs, time, and other overheads in traditional vaccination 
programs (Goforth et al., 2006; Mitchell et al., 2006; Peterson and Krauss, 2006). 
Additionally, time for the production of protective antibodies in chickens can be shorten for 
several weeks by one-shot vaccine because of the enhanced adjuvant effects, like significant 
enhancement of antigen specific antibody response was induced by 2C5 within four days PI, 
providing quick protections against specific pathogens. However, despite the benefits of 
safety and efficiency, mass production of 2C5 based complex for vaccination in the poultry 
industry is least cost-effective. Adenoviral vectors expressing chimeric variants of antigen 
fused to the 2C5 may overcome cost and production issues. 
Taken together, similar to what occurs in mammalian systems, our results concluded that 
CD40-targeted antigen delivery is an effective strategy to improve the kinetics of adaptive 
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immunity on subunit vaccines in chickens. Immunopotentiation mediated by exogenous 2C5 
in chickens is antigen dependent, as noted for other adjuvants and other species. Not only the 
observed positive effect on induction with this 2C5 based complex might be used to resolve 
an established NE, but also to be utilized to develop more effective strategy for subunit 





















IN OVO ADMINISTRATION OF ADENOVIRUS-VECTORED CD40 TARGETING 
VACCINE AGAINST C. PERFRINGENS α-TOXIN 
 
Introduction 
Modern broiler chickens all over the world have been threatened since the appearance 
of necrotic enteritis (NE) in 1961 (Parish, 1961), which is generally believed to be mainly 
caused by α-toxin secreted by Clostridium perfringens type A (Cooper and Songer, 2009). It 
is one of the most economically important enteric diseases in broiler chickens, which results 
in outbreaks with substantial mortality. C. perfringens is a spore forming Gram-positive 
anaerobic bacteria that can be found in the soil, feed, and intestine of chickens, but they are 
more commonly isolated in large numbers in poultry farms (Lee et al., 2011). C. perfringens 
is a normal inhabitant of chicken intestine in low numbers, which has no apparent negative 
impact on chickens. However, C. perfringens becomes pathogenic under some predisposing 
circumstances, such as coccidiosis, mycotoxins, and environmental stress (McReynolds et al., 
2004). Under these circumstances, C. perfringens type A can cause a spectrum of diseases in 
chickens including NE, cholangiohepatitis, diarrheal illness, and some subclinical / mild 
diseases, which results in depression of the flock growth rate and high economic losses 
(Williams, 2005). The standard approach in the poultry industry to protect chickens against 
these diseases is through the use of antibiotic feed additives, which have been used for many 
years but are now forbidden (Lee et al., 2011). As a consequence, NE has now become a 
serious threat to poultry producers, and antibiotic-free poultry products are highly demanded 
on markets; it is therefore essential to investigate methods to efficiently minimize exposure 
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of chickens to pathogenic factors of C. perfringens, and improve clinical efficacy of currently 
available vaccination strategies against NE. Immunization of broiler chickens with C. 
perfringens toxoid vaccine helps reducing the incidence and severity of NE and protecting 
intestinal integrity against clostridial infection (Saleh et al., 2011). Vaccination seems to be 
an interesting and successful alternative for the control of NE in broilers without the use of 
antibiotic feed additives. To vaccinate chickens in great numbers within a short time frame in 
response to an outbreak of NE, practical vaccines have to be produced rapidly and 
inexpensively, and have to elicit protective immunity in a single-dose regimen without 
involving labor-intensive procedures. Using vectored adenovirus vaccines for in ovo 
vaccination covers all these requirements (Tatsis and Ertl, 2004). 
Vectored adenoviruses have tremendous potential in both research and therapeutic 
applications, especially for expression of recombinant proteins in host cells (Hermening et al., 
2004). Introducing recombinant DNA coding for interesting antigens into host cells by 
adenovirus provides many advantages. First, adenovirus remains epichromosomal after 
entering cells, which does not activate or inactivate host genes (Zhang et al., 1994). Second, 
replication-defective adenovirus, such as vectored adenovirus type 5 (Ad5), can be produced 
at a large scale within a short period at low cost (O'Brien et al., 2009). Finally, Ad5 can 
transduce either dividing or non-dividing cells through many routes (Avakian et al., 2007), 
which is very useful for in ovo vaccination strategies. Another advantage of using Ad5 as 
vaccine is that the hexon protein on adenovirus is highly immunogenic and can efficiently 
elicit innate immune responses. Production of pro-inflammatory cytokines can be enhanced 
in the immunized animal, which then promotes activation, development, and differentiation 
of dendritic cells. Mature dendritic cells can further activate antigen-specific CD4 and CD8 
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T-cells, and then adaptive immunity can be greatly enhanced (Zandvliet et al., 2010). High 
administration doses (1×108 to 5×108 infectious units) for a single vaccination is practical 
when using Ad5, which allows subunit vaccines to overcome their inherently poor 
immunogenicity (Josefsberg and Buckland, 2012). 
Ad5 has also emerged as a promising alternative to conventional vaccines for in ovo 
administration because the use of recombinant adenovirus could eliminate the need for 
booster vaccinations and post-vaccination reactions or local reactions typical caused by 
vaccines made from live or inactivated organisms (Williams and Hopkins, 2011). 
In ovo vaccination with Ad5 expressing antigens of high pathogenic avian influenza 
virus (HPAIV) has been assessed, and protective immune responses against HPAIV were 
reported in several studies (Singh et al., 2010; Breedlove et al., 2011; Mesonero et al., 2011). 
These in ovo conventional Ad5 vaccines against HPAIV have been considered to be more 
effective, cheaper, and safer than classic subunit vaccines (Josefsberg and Buckland, 2012). 
In ovo vaccination with Ad5 also eliminate the possibility of interference with the maternal 
immunity and/or other possibilities of attenuated viral vaccines from becoming latent in 
vaccinated birds. Using Ad5 vaccines also allows the use of the Differentiating Infected from 
Vaccinated Animals (DIVA) strategy because no possibility of recombination reaction will 
occur between recombinant Ad5 and target pathogens, especially pathogenic bacteria, in the 
environment (Capua et al., 2004). 
One of the methods to increase immunogenicity of Ad5 vaccine is using molecular 
adjuvants (Mesonero et al., 2011). The use of molecular adjuvants, like chicken CD154, is 
also suggested to give Ad5 vaccine the ability to induce quick protective humoral responses 
under emergency conditions, even though in ovo vaccination (Breedlove et al., 2011). CD154 
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is a glycoprotein expressed as a type II integral membrane protein mainly on activated T-
cells (van Kooten and Banchereau, 2000). This molecule belongs to the TNF superfamily and 
has been defined as the most important co-stimulator for activating APCs, especially for B-
cells, through the CD40 signaling pathway (Zan et al., 1998). The interaction of CD40-
CD154 is also necessary for clonal expansion, germinal center formation, isotype switching, 
and formation of memory on B-cells (Banchereau et al., 1994). Several studies have shown 
that murine CD154 administered individually with T-cell dependent /independent antigens, 
or as a fusion protein can function as a molecular adjuvant, which enhances adaptive 
immunity and protection against diseases (Mackey et al., 1997). In avian species, the 
adjuvant effect of CD154 was first demonstrated by immunization of ducks with hepatitis B 
virus mixed with duck CD154, which was used as a model for infection of humans with 
hepatitis B virus (Gares et al., 2006). Several studies have shown that chicken CD154 
(chCD154) can act as a molecular adjuvant enhancing the immune response (Layton et al., 
2009; O'Meara et al., 2010). Additionally, significant specific humoral and cellular immune 
responses against HPAIV were induced in chickens immunized with the Ad5 expressing 
chCD154-hemagglutinin (HA) chimeric protein (Naskalska et al., 2009; Mesonero et al., 
2011). Cellular immune responses and HA-specific antibody titers were significantly higher 
than those induced by Ad5 expressing HA alone (Mesonero et al., 2011). 
Agonistic mAb/scFv against chCD40 have great potential as immunological adjuvants, 
and its partial functional equivalence with chCD154 has been demonstrated (Chen et al., 
2010). We have shown that agonistic monoclonal anti-chCD40 antibody (designated 2C5) 
could induce significant isotype switched antibody responses against a hapten that was 
biologically complexed to 2C5 only 4-days post-immunization (Chen et al., 2012). Based on 
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strong scientific evidence and extensive experience with clostridial vaccines for mammals, 
some recent studies have been carried out on C. perfringens type A/C toxoid and have shown 
promising results (Saleh et al., 2011). However, mice immunized intraperitoneally with a 
recombinant C-terminal of Cpα (CpαCD) had transient and localized lesions compared to 
sham immunized mice upon challenge with C. perfringens type A (Titball et al., 1993). After 
a high dose challenge (3.74 x 109 cfu), there were no survivors in the control group, whereas 
90% of the mice in the immunized group survived. These results not only demonstrate the 
usefulness of the CpαCD as an immunogen for inducing protective immune responses, but 
also suggest its candidacy for vaccine development other than toxoids (Stevens et al., 2004). 
In this chapter, the adjuvant capacity of agonistic anti-chCD40 scFv was combined 
with a delivery system based on an adenoviral vector to create a vaccine [Ad-(CD6-DAG1-
CpαCD-FLAG)] for in ovo vaccination, which can potentially induce immunoneutralizing 
antibodies against Cpα. With the same adenoviral vector platform previously evaluated in 
many studies on AIV by in ovo administration, DAG1-CpαCD-FLAG can be expressed and 
secreted by transduced chicken embryonic cells, and then actively target CD40 on APCs. We 
postulated that the agonistic anti-chCD40 scFv fused to CpαCD gene could bind to CD40 on 
the cell surface of chicken APCs, especially B-cells, and enhance their activation and 
differentiation through the well-characterized CD40 signaling,  in order to induce quick and 
strong CpαCD-specific IgA responses. The efficacy of in ovo vaccination of broilers with Ad-
(CD6-DAG1-CpαCD-FLAG) in controlling the NE was evaluated by C. perfringens type A 




Materials and methods 
Development of agonistic scFv against chCD40 
The agonistic anti-chCD40 scFv diabody (designated DAG1) used in this study was 
kindly provided by Dr. Daad Abi-Ghanem (Department of Poultry Science, Texas A&M 
University). Briefly, reverse transcription was used to clone cDNA from the splenocytes 
harvested from mice hyper-immunized against recombinant chCD40ED and the genes 
encoding the VH and VL domains were amplified by separate asymmetric PCR. VH and VL 
domains then linked by overlap-extension PCR and this anti-chCD40 scFv gene was 
modified to contain sequences encoding CD6 secretory signal sequence and HA-tag at its 5’ 
and 3’-end, respectively. The resultant anti-chCD40 scFv was designated as DAG1. Binding 
of DAG1 to chCD40 was verified by immunocytochemical staining on cells constantly 
expressing full-length chCD40 using purified DAG1 and an alkaline phosphatase conjugated 
anti-HA secondary antibody (Roche, South San Francisco, CA) as detecting reagents. DAG1 
was further cloned into a pCMV vector for expression in FreeStyle™ 293 cells, and the 
biological function of purified DAG1 was assessed through NO production in HD11 
macrophages and agglutination of DT40 cells (Abi-Ghanem et al., 2011). 
 
Cloning of CD6-DAG1-(G4S)3 
Primers used to amplify the gene encoding CD6-DAG1 with the addition of 
hydrophobic linker (Gly-Gly-Gly-Gly-Ser)3 [(G4S)3] at its 3’ end are listed in Table 2. The 
reverse primer DAG1-(G4S)3-Rev introduced the underlined nucleotides encoding a 
hydrophobic linker (G4S)3, which was used for linking DAG1 to CpαCD-FLAG. The CD6-
DAG1-(G4S)3 was amplified by PCR using pCMV-(CD6-DAG1-HA) as template and primer 
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pairs of SmaI-CD6-Fwd / DAG1-(G4S)3-Rev. Briefly, 100ng pCMV-(CD6-DAG1-HA) and 
2.5µL of each primer (10µM) were added into 25µL Phusion High-Fidelity PCR Master Mix 
(New England Biolabs, Ipswich, MA) in a PCR tube, and the final volume was adjusted to 
50µL with MQ-H2O. The amplification reaction was run in a thermal cycler with the 
following program: initial denaturation at 98oC for 30 seconds, 40 cycles consisting of 
denaturation at 98oC for 15 seconds, annealing at 55oC for 15 seconds, and extension at 72oC 
for 45 seconds, and was ended with a final extension step of 10 min at 72oC. PCR product 
with the expected size (933bp) was agarose gel purified and used for linking to (G4S)3-
CpαCD-FLAG. 
 
Table 2: Primers for cloning CD6-DAG1-(G4S)3 






Generation of irrelevant control scFv diabody: CD6-3G4 diabody 
3G4 scFv monomer (designated as 3G4m) was prepared using cDNA generated from a 
hybridoma that secretes a Neospora caninum apical antigen-specific mouse IgG2b mAb 
3G4/20 (Baszler, T. V. 2004. unpublished). In this study, 3G4 monomer was modified to a 
diabody format as control scFv (designated as 3G4d) similar to the DAG1 diabody. pCMV-
(CD6-3G4m-FLAG) was kindly provided by Dr. Waithaka Mwangi (Department of 
Veterinary Pathobiology, Texas A&M University) as template for cloning of CD6-3G4d. 
Primers used to modify CD6-3G4m-FLAG to CD6-3G4d-(G4S)3 are listed in Table 3. For 
cloning the VL domain of 3G4, the reverse primer VL-GGSSRSS-Rev contained the 
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underlined nucleotides encoding a hydrophobic short linker (GGSSRSS), which was used for 
linking 3G4 VL domain to 3G4 VH domain. The CD6-3G4 VL domain was amplified by PCR 
using pCMV-(CD6-3G4m-FLAG) as template and primer pairs of SmaI-CD6-Fwd / VL-
GGSSRSS-Rev. Briefly, 100ng pCMV-(CD6-3G4m-FLAG) and 2.5µL of each primer (10µM) 
were added into 25µL Phusion High-Fidelity PCR Master Mix in a PCR tube and the final 
volume was adjusted to 50µL with MQ-H2O. All amplification reactions were run in a 
thermal cycler with the following program: initial denaturation at 98oC for 30 seconds, 40 
cycles composed of denaturation at 98oC for 15 seconds, annealing at 55oC for 15 seconds, 
and extension at 72oC for 45 seconds, and was ended with a final extension step of 10 min at 
72oC. PCR product with the expected size (498bp) was agarose gel purified. 
For cloning the VH domain of 3G4, the forward primer GGSSRSS-VH-Fwd contained 
the underlined nucleotides coding for a hydrophobic short linker (GGSSRSS), which was 
used for linking the 3G4 VH domain to 3G4 VL domain. The reverse primer VH-(G4S)3-Rev 
contained the underlined nucleotides coding for (G4S)3, which was used for linking CD6-
3G4d to CpαCD-FLAG. The 3G4 VH domain was amplified by PCR using pCMV-(CD6-
3G4m-FLAG) as template and primer pairs of GGSSRSS-VH-Fwd / VH-(G4S)3-Rev. Briefly, 
100ng pCMV-(CD6-3G4m-FLAG) and 2.5µL of each primer (10µM) were added into 25µL 
Phusion High-Fidelity PCR Master Mix in a PCR tube and the final volume was adjusted to 
50µL with MQ-H2O. The amplification reaction was run in a thermal cycler with the 
following program: initial denaturation at 98oC for 30 seconds, 40 cycles consisting of 
denaturation at 98oC for 15 seconds, annealing at 55oC for 15 seconds, and extension at 72oC 
for 45 seconds, and was ended with a final extension step of 10 min at 72oC. PCR product 
with the expected size (387bp) was agarose gel purified. 
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CD6-3G4-VL-GGSSRSS and GGSSRSS-3G4-VH-(G4S)3 were joined using the 
GGSSRSS linker in an assembly reaction. When the GGSSRSS of CD6-3G4-VL-GGSSRSS 
anneals to the GGSSRSS of GGSSRSS-3G4-VH-(G4S)3, a fill-in reaction is primed in the 
presence of Phusion High-Fidelity DNA Polymerase. For this reaction to proceed efficiently, 
approximately equal molar quantities of CD6-3G4-VL-GGSSRSS and GGSSRSS-3G4-VH-
(G4S)3 were added into 25µL Phusion High-Fidelity PCR Master Mix in a PCR tube, and the 
tube was placed in a thermocycler with the following program: initial denaturation at 98oC 
for 30 seconds, 10 cycles composed of denaturation at 98oC for 1 minutes, annealing at 50oC 
for 15 seconds, and extension at 72oC for 45 seconds, and was ended with a final extension 
step of 10 min at 72oC. In the second round of PCR, the assembled CD6-3G4d-(G4S)3 was 
amplified by PCR using assembled and filled-in PCR product from the previous step as 
template and primer pairs of SmaI-CD6-Fwd and VH-(G4S)3-Rev. Briefly, 100ng assembled 
and filled-in CD6-3G4d-(G4S) and 2.5µL of each primer (10µM) were added into 25µL 
Phusion High-Fidelity PCR Master Mix (New England Biolabs) in a PCR tube, and the final 
volume in the tube was adjusted to 50µL with MQ-H2O. The amplification reaction was run 
in a thermal cycler with the following program: initial denaturation at 98oC for 30 seconds, 
40 cycles composed of denaturation at 98oC for 15 seconds, annealing at 55oC for 15 seconds, 
and extension at 72oC for 45 seconds, and was ended with a final extension step of 10 min at 
72oC. 
PCR product with the expected size (840bp) was agarose gel purified and cloned into 
pcr4-TOPO (Invitrogen), and the DNA sequence of CD6-3G4d-(G4S)3 was confirmed by 
DNA sequencing. Positive clones were used as template for amplifying CD6-3G4d-(G4S)3 
with the CD6-3G4d-CpαCD-FLAG chimera as a negative control. 
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Table 3: Primers for converting 3G4 scFv monomer to diabody 












Preparation of C. perfringens genomic DNA 
C. perfringens strain NRRL B-23706 (Southern Plains Agricultural Research Center, 
College Station, TX) was grown in PYG medium [2% (w/v) peptone, 0.5% (w/v) glucose, 
1% (w/v) yeast extract in MQ-H2O supplemented with 2mM NaCl, 3mM cysteine 
hydrochloride, 80µM CaCl2, 65µM MgSO4, 0.3mM K2HPO4, 0.3mM KH2PO4, and 5mM 
NaHCO3; pH was adjusted to 7.2] in an atmosphere of 5% CO2, 5% H2, and 90% N2 
overnight. Genomic DNA of C. perfringens was purified using MasterPure™ Gram Positive 
DNA Purification Kit (Epicentre® Biotechnologies, Madison, Wisconsin). One mL of an 
overnight C. perfringens culture was pelleted by centrifugation. The bacterial pellet was 
resuspended in 150µL Tris-EDTA buffer (TE buffer).  One µL Ready-Lyse lysozyme was 
added into the bacterial suspension, and the lysis reaction of the bacterial cell wall was 
allowed to proceed for 30 minutes at 37°C. For maximum bacterial cell wall lysis, bacterial 
crude lysate was further mixed thoroughly with 150µL Proteinase K / Gram Positive Lysis 
Solution and incubated for 15 minutes at 65°C. Bacterial debris was precipitated by adding 
175µL MPC Protein Precipitation Reagent and removed by centrifugation. Trace RNA was 
removed by addition of 1µL RNase A (5µg/µL) (SIGMA) and incubation for 30 minutes at 
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37°C. Genomic DNA was precipitated by addition of 500µL isopropanol with end-over-end 
mixing for 10 minutes at room temperature. Genomic DNA was then pelleted by 
centrifugation and washed with 70% ethanol three times. The genomic DNA pellet was air-
dried in a laminar flow hood for 30 minutes and then resuspended in 50µL TE buffer. 
Concentration of genomic DNA was determined on the NanoDrop. 
 
Cloning cDNA encoding (G4S)3-CpαCD-FLAG 
Primers used to amplify the gene encoding (G4S)3-CpαCD-FLAG were listed in Table 4. 
The forward primer (G4S)3-CpαCD-Fwd contained the underlined nucleotides encoding 
(G4S)3, which was used for linking the CpαCD gene to DAG1 / 3G4d. The reverse primer 
CpαCD-FLAG-Rev contained the underlined nucleotides introducing a FLAG tag 
(DYKDDDDK) at the 3’ end, which was used for detecting complete protein expression of 
CD6-DAG1-CpαCD-FLAG / CD6-3G4d-CpαCD-FLAG. The (G4S)3-CpαCD-FLAG was 
amplified by PCR using C. perfringens genomic DNA as template and primer pairs of 
(G4S)3-CpαCD-Fwd and CpαCD-FLAG-Rev. Briefly, 100ng C. perfringens genomic DNA and 
2.5µL of each primer (10µM) were added into 25µL Phusion High-Fidelity PCR Master Mix 
(New England Biolabs) in a PCR tube, and final volume in the tube was adjusted to 50µL 
with MQ-H2O. The amplification reaction was run in a thermal cycler with the following 
program: initial denaturation at 98oC for 30 seconds, 40 cycles composed of denaturation at 
98oC for 15 seconds, annealing at 55oC for 15 seconds, and extension at 72oC for 45 seconds, 
and was ended with a final extension step of 10 min at 72oC. PCR product with the expected 
size (618bp) was agarose gel purified and cloned into pcr4-TOPO vector (Invitrogen), and 
DNA sequence of (G4S)3-CpαCD-FLAG was confirmed by sequencing. Positive clones were 
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used as template for amplifying (G4S)3-CpαCD-FLAG for CD6-DAG1-CpαCD-FLAG and 
CD6-3G4d-CpαCD-FLAG cloning. 
 
Table 4: Primers for cloning (G4S)3-CpαCD-FLAG 








Cloning of CD6-DAG1-CpαCD-FLAG / CD6-3G4d-CpαCD-FLAG 
Primers used to amplify the gene coding for CD6-DAG1-CpαCD-FLAG / CD6-3G4d-
CpαCD-FLAG were listed in Table 5. CD6-DAG1-(G4S)3 / CD6-3G4d-(G4S)3 and (G4S)3-
CpαCD-FLAG were joined into a single chain by attachment of the (G4S)3 linker in an 
assembly reaction. When the (G4S)3 of  CD6-DAG1-(G4S)3 / CD6-3G4d-(G4S)3 anneals to the 
(G4S)3 of (G4S)3-CpαCD-FLAG, they prime a fill-in reaction in the presence of Phusion High-
Fidelity DNA Polymerase. For this reaction to proceed efficiently, approximately equal 
molar quantities of CD6-DAG1-(G4S)3 / CD6-3G4d-(G4S)3 and (G4S)3-CpαCD-FLAG were 
added into 25µL Phusion High-Fidelity PCR Master Mix (New England Biolabs) in a PCR 
tube, and the tube was placed in a thermocycler with the following program: initial 
denaturation at 98oC for 30 seconds, 10 cycles composed of denaturation at 98oC for 1 
minutes, annealing at 50oC for 15 seconds, and extension at 72oC for 45 seconds, and was 
ended with a final extension step of 10 min at 72oC. In the second round of PCR, the 
assembled CD6-DAG1-CpαCD-FLAG / CD6-3G4d-CpαCD-FLAG was amplified by PCR 
using assembled and filled-in PCR product from the previous step as template and SmaI-
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CD6-Fwd and CpαCD-FLAG-Rev primer pairs. Briefly, 100ng assembled and filled-in PCR 
product and 2.5µL of each primer (10µM) were added into 25µL Phusion High-Fidelity PCR 
Master Mix (New England Biolabs) in a PCR tube, and final volume in the tube was adjusted 
to 50µL with MQ-H2O. The amplification reaction was run in a thermal cycler with the 
following program: initial denaturation at 98oC for 30 seconds, followed by 40 cycles 
composed of denaturation at 98oC for 15 seconds, annealing at 55oC for 15 seconds, and 
extension at 72oC for 45 seconds, and was ended with a final extension step of 10 min at 
72oC. PCR products with the expected size (CD6-DAG1-CpαCD-FLAG: 1506bp; CD6-3G4d-
CpαCD-FLAG: 1410bp) were agarose gel purified and then cloned into pcr4-TOPO 
(Invitrogen), and DNA sequence of CD6-DAG1-CpαCD-FLAG / CD6-3G4d-CpαCD-FLAG 
was confirmed by DNA sequencing. Positive clones were used as template for amplifying 
CD6-DAG1-CpαCD-FLAG / CD6-3G4d-CpαCD-FLAG, to be further used for adenovirus 
vector construction. 
 
Table 5: Primers for cloning CD6-DAG1-CpαCD-FLAG / CD6-3G4d-CpαCD-
FLAG 






Cloning of pDONR-(CD6-DAG1-CpαCD-FLAG) / pDONR-(CD6-3G4d-CpαCD-FLAG) 
PCR was used to efficiently produce attB1- and attB2-flanked CD6-DAG1-CpαCD-
FLAG / CD6-3G4d-CpαCD-FLAG open reading frame (ORF) fragments. Universal attB1 and 
attB2 adaptor primers (Table 6) with two chimeric sequences were used to integrate 
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complete attB1 and attB2 sites into the ORF amplicon. Phusion® High-Fidelity DNA 
Polymerase was employed to amplify the predicted ORF with high fidelity. The 
amplification was performed, according to the protocol from Invitrogen in a 50µL reaction 
mixture containing 10µL of 5x Phusion HF Reaction Buffer, 1µL of dNTPs (10mM), 2.5µL 
of each primer (10µM), 0.5µL of Phusion DNA polymerase and 1µL of template. The attB x 
attP (BP) recombination reaction directed by BP clonase was carried out between the PCR 
product and destination vector (pDONRTM 221) according to the Invitrogen’s protocols 
(Invitrogen). Briefly, PCR product of right size was agarose gel purified and mixed with 
150ng pDONRTM 221 vector in a 1.5mL microcentrifuge tube at room temperature. BP 
ClonaseTM II enzyme mix (Invitrogen) was thawed on ice for two minutes, and then 2µL BP 
ClonaseTM II enzyme mix was added to the reactant from the previous step. BP 
recombination reaction was allowed to proceed at room temperature for one hour. The 
reaction was terminated by adding 1µL Proteinase K solution (Invitrogen), followed by 10-
minute incubation at 37oC. One µL of each BP recombination reactant was used for 
transformation into 50µL One Shot® OmniMAXTM 2 T1 phage-resistant chemically 
competent cells (Invitrogen). Two hundred and fifty µL S.O.C. medium was added to the 
cells, which were incubated at 37oC for one hour with shaking. One hundred µL of each 
transformation was plated onto LB plate [1% tryptone (w/v), 0.5% yeast extract (w/v), 1% 
NaCl (w/v), and 1.5% agar (w/v) in MQ-water] containing Kanamycin (50µg/mL). Five 
colonies were picked up and cultured overnight in LB medium [1% tryptone (w/v), 0.5% 
yeast extract (w/v), 1% NaCl (w/v)] containing Kanamycin (50µg/mL). The next day, 
plasmid DNA was isolated using the PureLinkTM HQ Mini Plasmid Purification Kit 
(Invitrogen). All plasmid DNA was analyzed by restriction digestion and PCR to confirm the 
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presence and correct orientation of the inserted gene. Positive clones were further confirmed 
by DNA sequencing. CD6-DAG1-CpαCD-FLAG) and CD6-3G4d-CpαCD-FLAG on pDONR 
was further cloned into pAd/CMV/V5-DEST™ vector (Invitrogen) separately by attL x attR 
(LR) recombination reaction. 
 
Table 6: Primers for cloning attB1-(CD6-DAG1-CpαCD-FLAG)-attB2 and attB1-
(CD6-3G4d-CpαCD-FLAG)-attB2 








Cloning of pAd-(CD6-DAG1-CpαCD-FLAG) / pAd-(CD6-3G4d-CpαCD-FLAG) 
One hundred and fifty ng pDONR-(CD6-DAG1-CpαCD-FLAG) / pDONR-(CD6-3G4d-
CpαCD-FLAG) was mixed with 150ng pAd/CMV/V5-DEST™ vector in a 1.5mL 
microcentrifuge tube at room temperature. LR ClonaseTM II enzyme mix (Invitrogen) was 
thawed on ice for two minutes, and then 2µL LR ClonaseTM II enzyme mix was added to the 
reactant from the previous step. LR recombination reaction was allowed to proceed at room 
temperature for one hour. The reaction was terminated by adding 1µL proteinase K solution 
(Invitrogen), and then incubated at 37oC for 10 minutes. One µL of each LR reaction was 
used for transformation of 50µL One Shot® TOP10 Competent Cells (Invitrogen). Briefly, 
cells and DNA were incubated on ice for 30 minutes; cells were then heat-shocked by 
incubating at 42oC for 30 seconds. Two hundred and fifty µL S.O.C. medium was added to 
the cells, which were then incubated at 37oC for one hour with shaking. One hundred µL of 
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each transformation reaction was plated onto LB plate containing carbenicillin (100µg/mL). 
Five colonies were picked up and cultured overnight in LB medium containing carbenicillin 
(100µg/mL). The next day, plasmid DNA was isolated using the PureLink™ HiPure Plasmid 
Miniprep Kit (Invitrogen). DNA sequencing was used to confirm the correct orientation of 
positive clones. The most promising clones were propagated, amplified, and maintained in 
the One Shot® ccdB Survival™ 2 T1R chemically competent E. coli. 
 
Expression of CD6-DAG1-CpαCD-FLAG / CD6-3G4d-CpαCD-FLAG in HEK 293A cells 
One day before transfection, 5 x 105 HEK 293A cells per well were seeded in a 6-well 
plate. Cells were supplemented with 2mL normal growth medium [10% (v/v) FBS, 1% (v/v) 
penicillin/streptomycin, 0.1mM MEM non-essential amino acids, and 2mM L-glutamine in 
DMEM] in each well. The next day, culture medium from HEK 293A cells was removed and 
replaced with 1.5mL normal OptiMEM® I Medium (Invitrogen) containing 10% FBS. For 
preparing DNA-Lipofectamine™ 2000 complex for transfection, 1µg pAd-(CD6-DAG1-
CpαCD-FLAG) / pAd-(CD6-3G4d-CpαCD-FLAG) was diluted in 250µL Opti-MEM
® I 
Medium, and 3µL Lipofectamine™ 2000 was also diluted in 250µL Opti-MEM® I Medium. 
After the 5 minute incubation at room temperature, diluted DNA and Lipofectamine™ 2000 
were combined by gentle mixing. The mixture was incubated for 20 minutes at room 
temperature to allow the DNA-Lipofectamine™ 2000 complexes to form. DNA-
Lipofectamine™ 2000 complex was added drop wise to each well, and mixed gently by 
rocking the plate back and forth. Cells were incubated overnight at 37°C in a CO2 incubator. 
The next day, the medium containing the DNA-Lipofectamine™ 2000 complex was removed 
and replaced with complete culture medium. Forty eight hours post-transfection, cells were 
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fixed with 500µL cold methanol in each well for 1 minute and blocked with PBST containing 
5% (w/v) BSA overnight at 4oC. Cells were then incubated with alkaline phosphatase 
conjugated anti-FLAG mAb (SIGMA) diluted (1:1000) in PBST containing 3% (w/v) BSA 
for one hour at room temperature. The color reaction was developed by using SIGMAFAST™ 
Fast Red TR/Naphthol AS-MX substrate (SIGMA) per the manufacturer’s instructions, and 
terminated by addition of 0.1M EDTA. Specific staining was visualized using an inverted 
phase contrast tissue culture microscope. 
 
Production of recombinant adenovirus expressing CD6-DAG1-CpαCD-FLAG / CD6-3G4d-
CpαCD-FLAG 
One day before transfection, HEK 293A cells were seeded at 5x105 cells per well in a 
6-well plate. Cells were plated in 2mL complete culture medium. On the next day, culture 
medium was removed from cells and replaced with 1.5mL Opti-MEM® I Medium containing 
10% FBS. In order to completely expose the inverted terminal repeats (ITRs) (adenoviral late 
genes encoding the encapsidation signal) on adenoviral vectors, both pAd-(CD6-DAG1-
CpαCD-FLAG) and pAd-(CD6-3G4d-CpαCD-FLAG) were linearized by PacI digestion before 
transfection of HEK 293A cells. Digested DNA was purified using phenol/chloroform 
extraction followed by ethanol precipitation. Linear DNA was resuspended in MQ-water to a 
final concentration of 500ng/µL. To prepare DNA-LipofectamineTM 2000 complexes for 
transfecting HEK 293A cells, 2µg DNA was diluted in 250µL Opti-MEM® I Medium, and 
5µL Lipofectamine™ 2000 was gently mixed in 250 µL Opti-MEM® I Medium as well. 
After a 5-minute incubation at room temperature, diluted DNA and diluted Lipofectamine™ 
2000 were combined, mixed gently, and incubated for 20 minutes at room temperature to 
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allow the DNA-Lipofectamine™ 2000 complexes to form. HEK 293A cells were transfected 
by adding the DNA-Lipofectamine™ 2000 complexes drop wise to each well, then the plate 
was rocked back and forth gently to enhance transfection efficacy. Transfected cells were 
incubated at 37°C in a CO2 incubator overnight. The next day, the medium containing the 
DNA-Lipofectamine™ 2000 complexes was removed and replaced with complete culture 
medium. Forty eight hours post-transfection, transfected cells were trypsinized and contents 
of each well was transferred to a sterile 10cm cell culture petri dish. Cell culture medium was 
replaced with fresh, complete culture medium every 3 days. Twelve days post-transfection 
(around cytopathic effects were observed in 80% of the cells), adenovirus-containing cells 
were harvested by squirting cells off the plate with a 10mL serological pipette. Cells and 
adenovirus-containing medium were transferred to a sterile 15 mL conical tube. 
 
Preparation of adenovirus stock 
The tube containing harvested adenovirus-containing cells and medium was placed at -
80oC for 30 minutes. The tube was removed from -80oC and placed in a 37oC water bath for 
15 minutes to thaw. The freezing and thawing steps were repeated twice. Cell lysate was 
centrifuged at 3000 rpm for 15 minutes at room temperature to pellet the cell debris. The 
supernatant containing adenoviral particles was transferred to cryovials in 1mL aliquots. 
Adenovirus stocks were stored at -80°C. 
 
Amplification of adenovirus 
Three days before infection, HEK 293A cells were seeded at 3 x 106 cells per T175 
cell culture flask with complete culture medium. On the day of infection, cell density was 
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verified to be at 80-90% confluence before proceeding. One hundred µL adenovirus stock 
was added to the cells, and the cell culture flask was swirled gently to maximize infection 
efficiency. Cells were incubated in a CO2 incubator at 37
oC and infection was allowed to 
proceed until 80-90% of the cells had rounded up and were floating or lightly attached to the 
tissue culture dish. Adenovirus-containing cells were harvested by squirting cells off from 
the flask with a sterile 10mL serological pipet. Cells and supernatant were transferred to a 
sterile 50mL conical centrifuge tube. After centrifugation at 3000rpm for 15 minutes, 
supernatant was removed and cell pellets were placed at -80oC for 30 minutes. Frozen cells 
were then incubated in a 37oC water bath for 15 minutes to thaw. Freezing and thawing steps 
were repeated twice. Cell lysate was centrifuged at 3000rpm for 15 minutes at room 
temperature to pellet the cell debris. Supernatant containing viral particles was transferred to 
cryovials in 1mL aliquots. Amplified adenoviruses were stored at -80oC and proceed to viral 
tittering. 
 
Titration of adenovirus stock 
A particular challenge in the delivery of a gene by adenoviral vector is the accurate 
measurement of virus titer. QuickTiter™ Adenovirus Titer Immunoassay Kit (Cell Biolabs, 
San Diego, CA), which utilizes an antibody against adenovirus hexon proteins to visualize 
infected cells by immunocytochemical staining, was used to functionally titer infectivity of 
both Ad/CD6-DAG1-CpαCD-FLAG and Ad/CD6-3G4d-CpαCD-FLAG. Two and a half x 10
5 
HEK 293A cells were seeded in each well of a 24-well cell culture plate, and then incubated 
at 37oC with supplement of 5% CO2 for one hour. Immediately before infection, 10-fold 
serial dilutions of Ad/CD6-DAG1-CpαCD-FLAG / Ad/CD6-3G4d-CpαCD-FLAG ranging from 
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10-5 to 10-9 were prepared. One hundred µL of each diluted adenovirus sample was added to 
each well of this 24-well cell culture plate. Titrations were performed in triplicate to ensure 
accuracy. Infected HEK 293 cells were incubated at 37oC with supplement of 5% CO2 for 
two days. Forth eight hours post infection, infected HEK 293A cells were fixed by gently 
adding 0.5mL cold methanol down the side of each well of the 24-well cell culture plate. 
Cells were gently washed three times with PBST, and then blocked with PBST containing 
5% BSA at 4oC overnight. On the next day, 1X anti-hexon antibody solution was prepared by 
diluting 1000X stock in PBST containing 3% BSA. Two hundred fifty µL 1X anti-hexon 
antibody solution was added to each well. The plates were incubated at room temperature on 
an orbital shaker for one hour. Cells were gently washed three times with PBST. In the 
meantime, 1X secondary antibody (HRP-conjugated) solution was prepared by diluting 
1000X stock in PBST containing 3% BSA. Two hundred and fifty µL secondary antibody 
solution was added to each well, and the plate was incubated at room temperature on an 
orbital shaker for one hour. Cells were gently washed three times with PBST. DAB working 
solution prepared per manufacture’s manual for color development on positive cells. Two 
hundred and fifty µL freshly prepared DAB working solution was added to each well, and 
then the plate was incubated at room temperature on an orbital shaker for 10 minutes. Stained 
cells were counted in at least five separate fields per well using a light microscope and the 
10X objective. Average number of positive cells was counted per well, and viral titer 
[infectious units (ifu) / mL] was calculated by the formula below. 










In vitro expression of DAG1-CpαCD-FLAG and 3G4d-CpαCD-FLAG and assessment of 
their specific binding to chCD40 
HEK 293A cells were seeded in a 10cm cell culture petri dish at a density of about 
2.5×105 cells/cm2 in complete medium. After 3 days of confluence, cells were infected with 
Ad-(CD6-DAG1-CpαCD-FLAG) /Ad-(CD6-3G4d-CpαCD-FLAG) at a multiplicity of infection 
(MOI) of 1. Seventy-two hours post infection; 10mL cell culture supernatant was harvested 
and concentrated to 500µL using Pierce Protein Concentrator, 9K MWCO (Thermo 
Scientific). Specific binding of CD6-DAG1-CpαCD-FLAG and CD6-3G4d-CpαCD-FLAG to 
chCD40 were accessed by sandwich ELISA. Briefly, ELISA plates were coated with 
rchCD40ED and then incubated with concentrated DAG1-CpαCD-FLAG / 3G4d-CpαCD-FLAG 
from cell culture medium. Specific binding of DAG1-CpαCD-FLAG / 3G4d-CpαCD-FLAG 
was then detected by incubating with chicken serum against Cpα followed by horseradish 
peroxidase (HRP) conjugated rabbit anti-chicken IgG antibody (Thermo Scientific). 
 
Vaccination and challenge 
Since recombinant adenovirus in this study not only produces the CpαCD but the CpαCD 
fused with a CD40-targeting diabody, we hypothesized that substantially lower viral doses 
(3x108 to 3x109 ifu) would be sufficient to elicit proactive humoral responses. Cobb 500 
embryonated eggs of 18 days (E18) were used for all in ovo treatments. Based on the 
visibility of the embryo, a small hole was made through the air cell with a drill. In ovo 
vaccination of 45 embryonated eggs was completed by inoculation of Ad-(CD6-DAG1-
CpαCD-FLAG) / Ad-(CD6-3G4d-CpαCD-FLAG) from 3x10
8 to 3x109 ifu/dose diluted in 
300µL sterile PBS respectively. Recombinant adenovirus was injected into the allantoic 
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cavity of eggs (at a depth of one inch) using a 21-gauge needle. In addition, 45 eggs were in 
ovo inoculated with 300µL saline, 45 eggs with phospholipase C from C. perfringens 
(SIGMA) mixed with modified chitosan, and 45 eggs with Cpα peptide-KLH conjugate 
mixed with modified chitosan for controls. Vaccinated eggs were incubated at 37°C in an egg 
incubator until they hatched. Hatched chickens were maintained in floor pen in a biosafety 
level 2 climate-controlled room and provided with water and 55% wheat/corn-based broiler 
starter diet ad libitum. Modified chitosan is produced by deacetylation of chitin from the 
shells of shrimp and other sea crustaceans (Wang et al., 2011). Modified chitosan has been 
used as adjuvant for poultry vaccine for a long time, and the positive adjuvant effect of 
chitosan on antigen-specific cell-mediated immunity after chickens vaccination with live 
Newcastle disease vaccine was also reported (Rauw et al., 2010). On day 14 post hatch, 
chickens were starved for 24 hours before 30,000 oocysts of Eimeria maxima were 
administered orally to each chicken by gavage. In the meantime, two virulent C. perfringens 
strains (Cp641 and Texas A&M) were grown in cooked meat medium (CMM) for 24 hours 
at 37oC. Liquid thioglycolate medium was then inoculated with 3% (v/w) inoculum and then 
incubated at 37oC for 24 hours. The growth of C. perfringens at 24 hours was approximately 
108 colony-forming units per mL (CFUs). Four days post administration with Eimeria 
maxima, feed was withdrawn and each bird was orally challenged with 1.5mL C. perfringens 
Cp641 (108 CFU) and Texas A&M (108 CFU) strains. All experimental procedures and 
animal care were performed in compliance with all applicable federal and institutional animal 
use guidelines. The conditions for animal use here were approved by the Institutional Animal 
Care & Use Committee of the University of Arkansas. 
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Necropsy and weight gain 
Four days post C. perfringens challenge, all chickens were euthanized by CO2 
asphyxiation and all birds were then weighed individually. Their small intestines (duodenum 
to ileum) were examined for grossly visible lesions. Intestinal lesions were scored from 0 to 4, 
where 0 = no gross lesions; 1 = thin and friable wall; 2 = focal necrosis or ulceration (1-5 
foci); 3 = focal necrosis or ulceration (6-15 foci); 4 = diffuse necrotic typical of field cases. 
Blinding was employed to avoid scorer bias. 
 
Quantification of Cpα-specific serum IgG and tracheal IgA by ELISA 
The Cpα-specific immune responses were monitored by collecting serum and tracheal 
mucosal samples on day 4, day 11 post hatches, and 4 days post C. perfringens challenge. 
ELISA was used for quantification of Cpα-specific IgG and IgA antibody titers. 
For collecting mucosal IgA sample from chicken trachea, a 1-cm segment of trachea 
from each bird was collected in a 2mL microcentrifuge tube, and the trachea was suspended 
in cold PBS [1:1 (wt/vl)] containing 0.01M phenylmethylsulfonyl fluoride, 0.1% sodium 
azide, and 3% BSA. Mucosal IgA was sloughed off from the inner liner of trachea by 
vigorous vortexing for 30 seconds. The tube was centrifuged at 5000g for 30 min at 4°C, and 
the supernatant was collected and frozen at -20oC until use. 
Ninety-six-well-microtiter plates (Nunc) were coated with purified Cpα (United States 
Department of Agriculture, IA) diluted in coating buffer overnight at 4oC. Unadsorbed Cpα 
was removed, and non-specific binding was blocked by incubating with PBST containing 5% 
BSA overnight at 4oC. After blocking, coated plates were incubated with samples of diluted 
serum (1:100) / tracheal mucus suspension (1:5) in PBST containing 3% (w/v) BSA in 
 85
triplicate, as well as positive control (Cpα-specific chicken serum, 1:100) and negative 
control (normal chicken serum, 1:100) overnight at 4oC. After repeat washes with PBST, 
PBST diluted horseradish peroxidase conjugated rabbit anti-chicken IgY (H+L) (1:12,000) / 
horseradish peroxidase conjugated goat anti-chicken IgA (H+L) (1:3000) was added to the 
wells and incubated at room temperature for one hour. Plates were washed for several times 
with PBST, and the color reaction was developed using OptEIA™ TMB substrate (Beckton 
Dickinson) per the manufacturer’s instructions, and terminated by addition of 50µL 1N 
sulfuric acid per well. Absorbance at 450 nm [A450] was measured in a Wallac plate reader. 
The presence of Cpα-specific IgG / IgA was determined by relating the mean A(450) value 
of each serum sample / mucosal IgA to that of the chicken Cpα positive control serum. The 
relative levels of Cpα-specific IgG / IgA in all samples were determined and normalized by 
calculating the sample to positive (S/P) ratio as described in Chapter IV. Comparison of 
means of S/P values was performed using one-way analysis of variance (ANOVA) with least 
significant difference (L.S.D.) as multiple comparison tests. Student’s t-test was used to 
determine significant differences in means of S/P values between treatments across all groups, 
and S/P values of the SA-peptide complex group were used as baseline. All data were 
analyzed and generated using SPSS software (IBM, Armonk, New York). Statistical 
significance was determined at P < 0.05. 
 
Statistical analysis 
Lesion scores were compared using two-tailed Fisher’s exact test. Lesion scores were 
ranked from 0 to 4. A protective response was considered as birds with ≤ 1+ lesions. Body 
weight was analyzed using ANOVA. 
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Results and discussion 
CD6-3G4-VL (Fig. 12A) and 3G4-VH-(G4S)3 (Fig. 12B) were joined into a single chain 
with a GGSSRSS linker in an assembly PCR reaction. PCR product with the expected size 
(840bp, Fig. 12C) was successfully amplified, gel purified, and then cloned into pcr4-TOPO 
vector. Positive clones were confirmed by DNA sequencing. Pcr4-[CD6-3G4d-(G4S)3] was 





Fig. 12. Cloning of CD6-3G4d-(G4S)3 from CD6-3G4 scFv monomer. (A) CD6-3G4-VL: 498bp and (B) 
3G4-VH-(G4S)3: 387bp were amplified separately from CD6-3G4 scFv monomer. (C) CD6-3G4 scFv 
diabody with 3 x G4S linker at its 3’-end: 840bp was prepared by linking CD6-3G4-VL and 3G4-VH-
(G4S)3 with a short linker: GGSSRSS. 
 
CpαCD-FLAG (Fig. 13B and 14B) and CD6-DAG1 (Fig. 13A) / CD6-3G4d (Fig. 14A) 
were joined together by a 3 x G4S linker into a single chain by overlap PCR. PCR product 
with the expected size [CD6-DAG1-CpαCD-FLAG (1506bp) (Fig. 13C) and CD6-3G4d-
A B C 
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CpαCD-FLAG (1410bp) (Fig. 14C) were successfully amplified, gel purified, and then cloned 
into pcr4-TOPO vector. Positive clones were confirmed by DNA sequencing. Pcr4-CD6-
DAG1-CpαCD-FLAG / pcr4-CD6-3G4d-CpαCD-FLAG was used as template for amplifying 
attB1-(CD6-DAG1-CpαCD-FLAG)-attB2 / attB1-(CD6-3G4d-CpαCD-FLAG)-attB2 for a first 





Fig. 13. Cloning of CD6-DAG1-CpαCD-FLAG by overlap extension PCR. (A) CD6-DAG1 scFv diabody 
with 3 x G4S linker at its 3’-end: 933bp and (B) CpαCD-FLAG with 3 x G4S linker at its 5’-end: 618bp 













Fig. 14. Cloning of CD6-3G4d-CpαCD-FLAG by overlap extension PCR. (A) CD6-3G4 scFv diabody with 
3 x G4S linker at its 3’-end: 837bp and (B) CpαCD-FLAG with 3 x G4S linker at its 5’-end: 618bp were 
joined into a single chain, (C) CD6-3G4d-CpαCD-FLAG: 1410bp, by (G4S)3 linker in an assembly PCR 
reaction. 
 
attB1-(CD6-DAG1-CpαCD-FLAG)-attB2 (Fig. 15A) and attB1-(CD6-3G4d-CpαCD-
FLAG)-attB2 (Fig. 15B) were successfully amplified by PCR. The sizes of the amplicons 
were 1606bp and 1510bp, respectively, as expected in theory. CD6-DAG1-CpαCD-FLAG / 
CD6-3G4d-CpαCD-FLAG in the pDONR
® 221 vector was confirmed by PCR and DNA 
sequencing. CD6-DAG1-CpαCD-FLAG / CD6-3G4d-CpαCD-FLAG in the pDONR
® 221 
vector was successfully transferred to pAd/CMV/V5-DESTTM vector by LR recombination. 
Positive pAd(CD6-DAG1-CpαCD-FLAG) / pAd-(CD6-3G4d-CpαCD-FLAG) was purified and 
digested with Pac I enzyme. Two gene fragments with the length of 30 kb, and 2 kb were 
obtained and consistent with the expected fragment size. It is concluded that two recombinant 
adenovirus vectors were successfully constructed. Furthermore, two inserts in the 
recombinant adenovirus vector were both verified by DNA sequencing. 
 




Fig. 15. Cloning of (A) attB1-(CD6-DAG1-CpαCD-FLAG)-attB2: 1576bp and (B) attB1-(CD6-3G4d-CpαCD-
FLAG)-attB2: 1480bp. PCR was used to efficiently produce attB1- and attB2-flanked CD6-DAG1-CpαCD-
FLAG / CD6-3G4d-CpαCD-FLAG ORF fragment. Universal attB1 and attB2 adaptor primers with two 
chimeric sequences were used to integrate complete attB1 and attB2 sites into the ORF amplicon. 
 
To confirm that both chimeric proteins could be expressed, immunocytochemistry was 
used on HEK 293A cells transfected with pAd-(CD6-DAG1-CpαCD-FLAG) / pAd-(CD6-
3G4d-CpαCD-FLAG). Forty eight hours post-transfection, cells were fixed, blocked, and then 
stained with alkaline phosphatase conjugated anti-FLAG mAb. The specific recombinant 
chimeric protein DAG1-CpαCD-FLAG and 3G4d-CpαCD-FLAG expressed in HEK 293A 
cells was specifically detected by immunocytochemistry as shown in Fig. 16. 
Immunocytochemical staining clearly showed that the FLAG-positive cells were only 






Fig. 16. Expression of CD6-DAG1-CpαCD-FLAG (A) and CD6-3G4d-CpαCD-FLAG (B) in HEK 293A cells 
transfected with adenoviral vectors harboring the CD6-DAG1-CpαCD-FLAG / CD6-3G4d-CpαCD-FLAG 
gene. Forty eight hours post-transfection, expression of DAG1-CpαCD-FLAG / 3G4d-CpαCD-FLAG in 
transfected HEK 293A cells was visualized by red alkaline phosphatase (AP) staining (AP conjugated 
anti-FLAG mAb). 
 
In order to allow proper viral replication and packaging in HEK 293A cells, left and 
right viral ITRs of pAd-(CD6-DAG1-CpαCD-FLAG) / pAd-(CD6-3G4d-CpαCD-FLAG) need 
to be exposed by Pac I digestion before transfection of HEK 293A. Both pAd-(CD6-DAG1-
CpαCD-FLAG) / pAd-(CD6-3G4d-CpαCD-FLAG) were successfully linearized with Pac I (Fig. 
17). Ampicillin resistance gene (2074bp) and the pUC origin on the vectors, which is useless 
in adenovirus production, were removed by Pac I digestion. 
To determine whether host cells can express DAG1-CpαCD-FLAG or 3G4d-CpαCD-
FLAG after infection with recombinant adenovirus, HEK 293 cells were exposed to various 
concentrations of either Ad-(CD6-DAG1-CpαCD-FLAG) or Ad-(CD6-3G4d-CpαCD-FLAG) 
for 48 hours. As shown in Fig. 18, two chimeric proteins were readily detected by 
immunocytochemistry in HEK 293 cells infected with 1 multiplicity of infection (MOI) of 
each recombinant adenovirus. Furthermore, the amount of each FLAG-positive chimeric 
protein increased with increasing MOI of its corresponding recombinant adenovirus (data not 
shown). There was no detectable FLAG in cells infected with sham adenovirus (data not 
A B 
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shown). The chCD40 binding capacity of DAG1-CpαCD-FLAG / 3G4d-CpαCD-FLAG 
chimeric protein was confirmed by ELISA (Table 7). 
 
 
Fig. 17. Identification of recombinant pAd-(CD6-DAG1-CpαCD-FLAG) (lane1) and pAd-(CD6-3G4d-
CpαCD-FLAG) (lane 2) with Pac I digestion in 0.8% agarose gel. pUC origin and ampicillin resistance 
gene (2074bp) were released from both adenoviral vectors by Pac I digestion. Left and right viral ITRs of 
both adenoviral vectors were completely exposed for proper viral replication and packaging in HEK 
293A cells. 
 
Table 7: ELISA readouts [A(450)] indicated that only DAG1-CpαCD-FLAG has 















A(450) 1.30 0.90 0.75 0.04 
Chicken anti-Cpα serum (1:100, primary antibody) and HRP-rabbit anti-chicken 







Fig. 18. Immunocytochemical staining of FLAG-tagged chimeric protein expression in Ad-(CD6-DAG1-
CpαCD-FLAG) / Ad-(CD6-3G4d-CpαCD-FLAG) infected HEK 293A cells. HEK 293A cells were infected 
with Ad-(CD6-DAG1-CpαCD-FLAG) (A) or Ad-(CD6-3G4d-CpαCD-FLAG) (B) at MOI = 100 for 48 hours. 
After permeabilization, cells were incubated with AP-conjugated mouse anti-FLAG mAb, followed by 
color development using SIGMAFAST™ Fast Red TR/Naphthol AS-MX substrate.  
 
From practical and commercial perspectives, in ovo vaccination has to maintain high 
hatchability levels (≥90%) (Josefsberg and Buckland, 2012). However, in ovo vaccination 
with Ad-(CD6-DAG1-CpαCD-FLAG) at 3x10
8 / 3x109 ifu on E18 eggs resulted in a poor 
hatchability (68-72%). On the other hand, vaccination with control Ad vaccines (3x108 ifu) 
did not have significant adverse effects on the chicken embryos, and the hatchability (>80%) 
in this group is acceptable (Fig. 19). This result suggests that the dose of Ad-(CD6-DAG1-
CpαCD-FLAG) for in ovo vaccination needs to be optimized and lower doses (such as 3x10
6 
ifu) may be more practical. 
Compared to traditional field vaccine administration, in ovo vaccination helps close the 
window of susceptibility between early exposure to pathogens and post-hatch vaccination 
because both innate and adaptive immunity against specific pathogens were already 
stimulated in in ovo vaccinated embryos (Negash et al., 2004). Besides maternal antibody, in 
ovo vaccinated chicks have already developed an appreciable degree of protection by the 




Fig. 19. Embryonated eggs vaccinated with Ad-(CD6-DAG1-CpαCD-FLAG) in ovo had hatchability 
identical to those from control groups. 
 
We expected to observe robust mucosal immunity against Cpα and an improved IgA 
response in the Ad-(CD6-DAG1-CpαCD-FLAG) vaccinates as compared to controls. Besides 
Cpα peptide-KLH conjugate control group, chickens from other groups did not produce 
significant Cpα-specific IgA / IgG response (Fig. 20 and Fig. 21). Only chickens immunized 
in ovo with Cpα peptide-KLH conjugate mixed with modified chitosan produced a 
significant Cpα-specific IgG response (P < 0.01) 4 days post C. perfringens challenge (Fig. 
21). The toxicity of recombinant adenovirus expressing the truncated CpαCD when 
administered in ovo is not expected because toxicity of the alpha toxin is lost upon truncation 
(Williamson and Titball, 1993). 
Tregaskes and colleagues (Tregaskes et al., 2005) reported that overdose 
administration of chCD154 on chicken APCs causes APCs to undergo apoptosis instead of 
differentiation or development in vivo. In the mouse model, overdose administration of 
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agonistic anti-mouse CD40 can also cause apoptosis on splenic B-cells both in vivo and in 
vitro (Qi et al., 2004; Gao et al., 2012). Since hatchability data suggest that Ad-(CD6-DAG1-
CpαCD-FLAG) may have been over-administered to E18 eggs, the population of B-cells with 
BCRs, which recognized CpαCD, in GALT, especially Peyer's patch, and primary lymphoid 
organs may undergo apoptosis through the CD40 pathway, and this scenario can also be used 
to explain why no Cpα-specific antibody was found in chickens immunized with Ad-(CD6-
DAG1-CpαCD-FLAG) post hatch. However, apoptosis in chicken APCs caused by super-
optimal doses of DAG1 needs to be further elucidated. 
Protection of chickens against C. perfringens challenge in Ad-(CD6-DAG1-CpαCD-
FLAG) immunized chickens was assessed by body weight gains (Fig. 22), gross pathology at 
necropsy (Fig. 23), and mortality rate (Fig. 24) in the experiment. No significant increase in 
body weight gain was observed in chickens among all vaccine groups. Data of lesion scores 
and mortality also do not show any statistical difference among any of the vaccine groups. 
These results suggest that chickens immunized with Ad-(CD6-DAG1-CpαCD-FLAG) in ovo 
were not protected from C. perfringens challenge. Since no Cpα-specific antibody response, 
especially mucosal IgA, was detected in any bird post-vaccination besides Cpα peptide-KLH 










Fig. 20. Alpha-toxin specific mucosal IgA ELISA S/P values from Cobb 500 chickens immunized with 
different vaccines in ovo followed with challenge by C. perfringens Cp641 and Texas A&M strains. 
Trachea were collected at three time points: day 4, for determination of Cpα-specific IgA response after 
in ovo vaccination; day 11, mid-experiment for determination of pre-challenge Cpα-specific IgA response; 
and day 22, for determination of post-challenge Cpα-specific IgA response from chickens that survived 
the C. perfringens challenge. In each case, error bars represent standard deviations from the mean and 
the asterisks represent statistical significance (n=10; *P<0.05; **P<0.01; ***P<0.001) compared with Ad-
(CD6-3G4d-CpαCD-FLAG) control as determined by Student’s t-test. Embryonated eggs vaccinated in ovo 
with control 1: Saline; control 2: Cpα peptide-KLH conjugate mixed with modified chitosan; control 3: 
Phospholipase C from C. perfringens mixed with modified chitosan; control 4: 3x108 ifu Ad-(CD6-3G4d-
CpαCD-FLAG)(low); control 5: 3x10
9
 ifu Ad-(CD6-3G4d-CpαCD-FLAG)(high); treatment 1: 3x10
8
 ifu Ad-
(CD6-DAG1-CpαCD-FLAG)(low); treatment 2: 3x10
9




Fig. 21. Serum alpha-toxin specific IgG ELISA S/P values from all Cobb 500 chickens immunized with 
different vaccines in ovo followed with challenge by C. perfringens Cp641 and Texas A&M strains. Blood 
samples were collected at three time points: day 4, for determination of Cpα-specific IgG response after 
in ovo vaccination; day 11, mid-experiment for determination of pre-challenge Cpα-specific IgG response; 
and day 22, for determination of post-challenge Cpα-specific IgG response from chickens that survived 
the C. perfringens challenge. In each case, error bars represent standard deviations from the mean and 
the asterisks represent statistical significance (n=10; *P<0.05; **P<0.01; ***P<0.001) compared with Ad-
(CD6-3G4d-CpαCD-FLAG) control as determined by Student’s t-test. Embryonated eggs vaccinated in ovo 
with control 1: Saline; control 2: Cpα peptide-KLH conjugate mixed with modified chitosan; control 3: 
Phospholipase C from C. perfringens mixed with modified chitosan; control 4: 3x108 ifu Ad-(CD6-3G4d-
CpαCD-FLAG)(low); control 5: 3x10
9
 ifu Ad-(CD6-3G4d-CpαCD-FLAG)(high); treatment 1: 3x10
8
 ifu Ad-
(CD6-DAG1-CpαCD-FLAG)(low); treatment 2: 3x10
9
 ifu Ad-(CD6-DAG1-CpαCD-FLAG)(high) 
 
For broiler producers, in ovo vaccination is an attractive approach for vaccination of 
great numbers of birds against devastating diseases, such as IBDV (Williams and Zedek, 
2010). In ovo vaccination with recombinant adenovirus was demonstrated as an efficient 
method for controlling various infectious diseases, especially avian influenza (Breedlove et 
al., 2011). Another advantage of in ovo vaccination is fast (50,000 egg/hour) and uniform 
antigen delivery, and early protective immune responses can be elicited as early as the day of 
hatch. Compared with traditional field vaccination, using an in ovo vaccination strategy can 
greatly reduce labor cost and does not stress the birds. 
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Fig. 22. Chickens immunized in ovo with Ad-(CD6-DAG1-CpαCD-FLAG) did not have statistically 
different body weight gain compared to control groups after C. perfringens challenge (P = 0.084). 
 
 
Fig. 23. Groups of chickens immunized in ovo with Ad-(CD6-DAG1-CpαCD-FLAG) did not have 




Fig. 24. Groups of chickens immunized in ovo with Ad-(CD6-DAG1-CpαCD-FLAG) at either dose showed 
higher mortality after C. perfringens challenge than control groups. 
 
These preliminary data show that chickens vaccinated in ovo with Ad-(CD6-DAG1-
CpαCD-FLAG) at neither 3 x10
8 nor 3 x 109 ifu do not produce enhanced IgA or IgG 
responses and were susceptible to NE by C. perfringens challenge. Nevertheless, it is still 
tempting to speculate that robust and quick protective responses against α-toxin might be 
obtained under the same settings while administering lower adenovirus quantities in ovo for 
more controlled and efficient antigen delivery to the APCs and enhanced stimulation of Cpα-
specific B-cells. Another aspect in which this in ovo strategy can potentially be improved is 
to co-deliver another immunopotentiator, like chicken B-cell activating factor (chBAFF), by 
adenovirus. Ad5-chBAFF has potential as an immunopotentiator and IgA switch factor to 
also be used in combination with other in ovo or neonatal vaccines (Chen et al., 2009). 
Chicken BAFF (chBAFF) is a highly conserved cytokine that promotes the survival of 
splenic chicken B-cells in vitro (Schneider et al., 2004). In addition, recombinant chBAFF 
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induces the selective expansion of B-cells in the spleen and cecal tonsils when administered 
to young chickens (Schneider et al., 2004). The binding of recombinant human BAFF to 
chicken bursal B-cells also indicates conserved receptor ligand binding (Koskela et al., 2004). 
Finally, treatment of 3-day old chickens with chBAFF resulted in significantly increased 
antigen–specific mucosal IgA response compared to control birds (Kothlow et al., 2010), 
which strongly suggests that chBAFF functions as an isotype switching factor that promotes 
the production of mucosal sIgA, as is the case in mammals. Ad-chBAFF along with Ad-
(CD6-DAG1-CpαCD-FLAG) should be used for in ovo vaccination to enhance Cpα-specific 
IgA responses at the mucosal surface and to thereby improve protection against C. 






















SUMMARY AND CONCLUSION 
 
Summary 
Necrotic enteritis (NE) is an economically devastating enteric disease of chickens primarily 
caused by infection with C. perfringens type A. Vaccination is currently the most promising 
control strategy for controlling NE. Therefore, there is strong interest in immunological adjuvants 
with low reactogenicity but high potency to enhance immune responses. Arguably one of the most 
successful strategies to attain this end consists of attaching the antigen to an antibody against a co-
stimulatory cell surface receptor expressed by antigen-presenting cells (APC), such as CD40. 
Agonistic anti-CD40 antibodies not only target antigen delivery and activate B-cells, but also 
induce antibody class-switching on B-cells both in vitro and in vivo. The antibody class-switching 
is crucial because IgA is readily transported across the intestinal mucosa and is endowed with 
effector properties that are critical for the local humoral immune response. The central 
hypothesis here claims that in ovo vaccination with an adenovirus-vectored C-terminal 
domain of Cpα fused to an agonistic anti-chicken CD40 diabody vaccine capable of targeting 
antigen to APCs, which will improve mucosal IgA response and protection in chickens 
against NE. This hypothesis was tested through completion of the following specific 
experiments. 
In the first experiment, an agonistic monoclonal anti-chicken CD40 antibody 2C5 was 
produced and characterized. Extracellular domain of chicken CD40 was cloned from chicken 
splenocytes and then expressed in FreeStyle™ 293 cells for monoclonal antibody production. 
The specific binding of antibodies secreted by anti-chCD40 hybridomas to chCD40 were 
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screened by immunocytochemistry, flow cytometry, and immunoprecipitation on chicken 
APCs. Positive clones were further selected for their agonistic activities on chicken APCs. 
Agonistic activities of anti-chCD40 mAbs were assessed by enhancement on cellular 
proliferation of serum starved DT40 B-cells and production of NO by HD11 macrophages. 
Among all positive clones, 2C5 is the most promising and suggested to mimic partial 
biological functions of chicken CD154, and thus has great potential as an immunological 
adjuvant. 
In the second experiment, the potential of 2C5 as potentiator of a subunit vaccine 
consisting of a non-immunogenic peptide in five-week old chicks was assessed in an in vivo 
experiment. This 2C5 based vaccine complex was prepared by complexing biotinylated 2C5, 
streptavidin, and biotinylated peptide at a stoichiometric ratio of 2:1:2. Chicks (7 chicks / 
group) were immunized subcutaneously with 2C5-peptide complex at three dose levels (10µg, 
30µg, and 90µg) in the nape of the neck. A single subcutaneous immunization with any dose 
of this 2C5 based vaccine complex was able to generate significant peptide-specific IgG 
responses (P < 0.001) as soon as 4 days through 2 weeks post immunization. This result 
demonstrated that CD40-targeted antigen delivery is an effective strategy to enhance the 
adaptive immune response to subunit vaccines in chickens in terms of speed, duration and 
isotype class switching. 
A recombinant adenovirus expressing an agonistic anti-chCD40 single chain diabody 
(designed as DAG1) fused to C-terminal domain of C. perfringens α-toxin chimeric protein 
was tested for enhancement of mucosal IgA secretion and protection of chickens upon 
challenge while it was administrated by in ovo. No statistical significant difference was found 
on IgA / IgG response from any of vaccine groups during the experiment. After C. 
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perfringens challenge, lesion scores, body weight gain, and motality results conclude that no 
protection effect was found in chickens in ovo immunized with this recombinant adenovirus 
vaccine. Overdose administration of vaccine may be the reason why CD40 targeting 
hypothesis was rejected because overdose administration of agonistic anti-chCD40 diabody 
may cause chicken APCs, especially Cpα-specific B-cells, undergo apoptosis. The dose of 
recombinant adenovirus expressing DAG1-CpαCD for in ovo vaccination of E18 eggs needs 
to be optimized, and lower dose may be used for more accurate, controlled, and efficient 
stimulation on Cpα-specific B-cells and antigen delivery. 
 
Conclusion 
Specific binding of anti-chCD40 mAb to chCD40 was confirmed in vitro by 
immunocytochemistry and immunoprecipitation, and CD40 expression profile on chicken 
APCs was further confirmed by flow cytometry, indicating that 2C5 can be used for detailed 
screening of the expression level and distribution of chCD40 on various chicken cells and 
tissues. The identification of this potent activator of both chicken macrophages and B-cells 
will be useful in the further study of CD40L/CD40 interactions in the chicken, which is a 
valuable asset with regard to its potential use in vaccine development. Since accelerated, 
enhanced, isotyped-switched IgG response against a non-immunogenic peptide was only 
found in chickens immunized with 2C5-peptide complex, we conclude that this enhanced 
immunogenicity is due to the engagement of 2C5 with CD40 on APCs in vivo, by which 
directly activates peptide specific B-cells. This effect may be related to a better employ of 
this peptide by enhancing the engagement of 2C5 on the complex for B-cell activation 
simultaneously with CD40 on the surface of peptide-activated B-cells to induce the peptide-
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specific IgG response. The anti-CD40 mAb-based adjuvant action is extremely potent and 
may avoid the inflammatory side effects induced by most classical adjuvants.  
Chicken mucosal tissues are rich in APCs, we also expect that Ad-(CD6-DAG1-
CpαCD-FLAG) could induce efficient systemic and mucosal immune responses through the in 
ovo immunization route. However, neither statistical significant IgA / IgG response nor 
protection against C. perfringens challenge was found in chickens in ovo vaccinated with Ad-
(CD6-DAG1-CpαCD-FLAG). Our preliminary data suggests that over-dose administration of 
recombinant adenovirus may be the reason why no significant Cpα-specific IgA / IgG 
response was found in chickens in ovo vaccinated with Ad-(CD6-DAG1-CPαCD-FLAG). The 
variety of contributions of CD40 targeting to chicken APCs through in ovo administration 
attest to the great versatility of the CD40-CD154 pathway in contributing to both normal 
immune responses and protection against T-cell independent / dependent antigens, as well as 
the dangers powerful CD40-mediated activating signals pose for the development and 
progression of chronic inflammatory diseases and apoptosis on chicken APCs. 
The poultry industry is in urgent need of one-shot vaccines because it helps to save 
budget on fee from labor, time, and other overheads in traditional vaccination programs. 
Additionally, time for the production of protective antibodies in chickens can be shortening 
for several weeks by one-shot vaccine because of the enhanced adjuvant effects. This study 
has facilitated the design of approaches to apply CD40-targeting strategy while it attempts to 
improve the effects of subunit vaccines against a variety of chicken diseases. However, using 
optimized dose of Ad-(CD6-DAG1-CpαCD-FLAG) for in ovo vaccination is a tempting 
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